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 5 
Abstract 
 The chemotherapy drug cisplatin is used to treat a wide variety of cancers; however, it 
has a number of side effects, such as damage to hearing or balance functions of the ear defined as 
ototoxicity, that can limit its use.  The goal of this study was to use larval zebrafish as an in vivo 
model to investigate whether conjugation to gold nanoparticles (AuNPs) reduces cisplatin’s 
ototoxicity.  AuNPs-cisplatin conjugates were synthesized using a seeded-growth approach, and 
the loading of cisplatin on the nanoparticles was measured by inductively coupled plasma optical 
emission spectroscopy (ICP-OES).  The conjugates synthesized were found to contain too low of 
a concentration of cisplatin to perform ototoxicity testing with.  The results of systemic toxicity 
assays showed that the high (> 5 nM NPs) concentrations of AuNPs in the conjugates were 
themselves acutely toxic to zebrafish larvae.  The findings suggest that severe systemic toxicity 
reduces the feasibility of using larval zebrafish as a model to study the effects of AuNPs at high 
(> 5 nM NPs) concentrations, providing important information about the concentration-
dependence of AuNPs toxicity.  However, no conclusions could be made about whether 
nanoconjugation reduces cisplatin’s ototoxicity.    
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Introduction 
Cancer and Chemotherapy 
 For almost everyone, the word cancer evokes painful memories of a dearly beloved and 
departed friend or family member.  Cancer is a large group of diseases involving uncontrolled 
cell division that leads to the growth of malignant tumors.  As the average human lifespan has 
increased steadily in recent history, an increasing number of people are being diagnosed with 
cancer.  Rightly so, cancer has the reputation as a deadly disease, and as of 2008 cancer 
accounted for almost 14% of the global death rate (Jemal, 2011).  While advances in modern 
medicine over the past few decades have drastically decreased death rates from many illnesses, 
such as the two leading causes of death worldwide heart disease and infectious disease, cancer 
death rates have not decreased significantly (Varmus, 2006).  There is no cure for cancer, but 
clinicians use a wide variety of treatments to manage the disease.  The primary options for 
cancer treatment are surgery, radiation therapy, and chemotherapy all of which have the goal of 
completely eradicating cancerous cells, but unfortunately that goal is rarely achieved.  
Traditional chemotherapeutic drugs act by impairing cell division, and correspondingly they kill 
rapidly diving cells (Gerber, 2008).  Rapid cell division is one of the defining features of cancer 
cells, but there are also many cells in the body that divide rapidly under normal conditions.  As a 
result, chemotherapy not only kills cancer cells but also causes numerous common side effects 
by killing cells in the bone marrow, digestive tract, nervous system, and other healthy tissues 
(Love, 1989).  The severe toxicity often associated with chemotherapy limits the dose of drugs 
that can be given, and with the lower drug doses tumors often develop resistance to the treatment 
(Luqmani, 2005).  While there are certainly limitations to chemotherapy, chemotherapeutic drugs 
often offer clinicians the best chance to treat cancer patients.   
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Cisplatin 
History.  Cisplatin, or cis-diamminedichloroplatinum(II) [PtCl2(NH3)2], is a paradigmatic 
chemotherapeutic drug that is widely used to treat a variety of cancers [Figure 1].  The 
compound itself has a long and interesting history that 
began with its initial synthesis and description as 
Peyrone’s Salt in 1844 by the Italian chemist Michele 
Peyrone (Peyrone, 1844).  After its synthesis, the 
structure of Peyrone’s Salt was hotly debated for 
almost 50 years (Alderden, 2006).  The structure was finally elucidated in 1893 by the German 
chemist Alfred Werner who deduced its square planar configuration and distinguished between 
the cis and trans isomers (Werner, 1893).  Werner’s work with cisplatin played a part in his 
becoming the first inorganic chemist to win Nobel Prize, doing so in 1913, and the last one to do 
so for sixty years.  After its structural elucidation, cisplatin existed in obscurity for decades until 
the accidental discovery of biological activity by the American chemist Barnett Rosenberg in 
1965 (Rosenberg, 1965).  Rosenberg was trying to measure the effect of electrical currents on 
bacterial cell growth, but instead he found that a compound formed in a reaction between 
constituents of the bacterial solution and platinum electrodes inhibited cell division itself.  
Rosenberg isolated ten platinum compounds formed in the ammonium chloride solution and 
determined that the molecule with biological activity was in fact cisplatin (Rosenberg, 1967).  A 
very short time later, Rosenberg published results showing that cisplatin displayed potent 
antitumor activity in cancer model rats with solid tumors (Rosenberg, 1969).  Encouraging 
results in animal studies led to cisplatin entering clinical trials in 1971, and it was approved for 
cancer treatment by the U.S. Food and Drug Administration (FDA) in 1978 (Loehrer, 1984).  
Figure 1. Cisplatin structure. 
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Cisplatin’s translation from basic research discovery to clinical medicine occurred unthinkably 
fast by today’s standards, which indicates how much of a game-changing factor its introduction 
was for cancer treatment. 
Clinical Use.  Almost forty years after its serendipitous discovery, cisplatin is still one of the 
most successful anticancer drugs available.  Even though it was first approved for treatment over 
thirty-five years ago, cisplatin is still  prescribed as a first line treatment for many cancer 
diagnoses.  In fact, cisplatin and its few effective derivatives are used in the treatment regiments 
of more than 50% of cancer patients (Gasser, 2011).  Cisplatin’s early development and wide use 
to treat a variety of cancers has led to it being dubbed the “penicillin of cancer drugs,” a moniker 
that reveals its essential importance to chemotherapy (Trzaska, 2005).  When new cancer 
treatments are developed, cisplatin is often used at the reference standard to which the novel 
treatments are compared.  As one of the most popular chemotherapeutics, sales of cisplatin in the 
United States alone are about $500 million annually (Abu-Surrah, 2006).  Initially approved to 
treat testicular and ovarian cancer, it has since been found to be effective against a wide range of 
solid-tumor cancers, including malignancies of the lung, head, neck, and bladder (Hambley, 
2007).  Cisplatin is most effective against testicular cancer, with a cure rate of between 85-90%, 
which is particularly impressive considering the 10% cure rate before the drug’s introduction 
(Wang, 2005).  The drug is perhaps most famous for its role in helping cyclist Lance Armstrong 
win his battle against testicular cancer.  The clinical success of cisplatin spawned great interest in 
the use of metal compounds as chemotherapy agents, but even as researchers have learnt more 
about cisplatin’s mechanism of action they still have been unable to significantly improve upon 
its cytotoxicity with newer generations of drugs. 
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Mechanism of Action.  Although cisplatin was swiftly approved for treatment after the discovery 
of its cytotoxic activity, the exact mechanism by which cisplatin kills cells is still somewhat 
under debate.  After intravenous administration, the drug moves from venous blood into cells by 
both passive diffusion and active transport (Gately, 1993).  It had been postulated that cisplatin 
enters cells exclusively through passive diffusion, but evidence gathered over the past twenty 
years has implicated active mechanisms.  In cancer cells, the copper transporter Ctr1 (Ishida, 
2002) and the organic cation transporter Oct2 have been shown to play important roles in 
cisplatin uptake (Filipski, 2008).  Before the drug is able to react with its target, the neutral 
cisplatin molecule must be activated  by sequential aquation reactions that replace the cis-chloro 
ligands with water molecules (Hincal, 1979) [Figure 2].  The significant drop in chloride  
 
Figure 2.  Depiction of the path taken by cisplatin from i.v. injection to DNA-adduct formation, 
including both passive and active cellular uptake and the activating aquation process.  
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concentration in the cytoplasm relative to the blood facilitates the aquation of cisplatin (Davies, 
2000).  The aquated form of the drug is highly reactive and can be inactivated in the cytoplasm 
by reacting with many thiol-containing nucleophiles, such as glutathione (GSH) (Kelland, 1993).  
After aquation, cisplatin is believed to exert its cytotoxicity by binding to DNA bases and 
forming adducts that eventually lead to cell death via apoptosis (Pinto, 1985). 
 Cisplatin has been shown in vitro and in vivo to covalently bond with the nucleophillic N7 
atom of purine bases of DNA to form interstrand and instrastrand crosslinks (Eastman, 1987; 
Jung, 2007) [Figure 3].  Cisplatin-nucleobase binding occurs preferentially with intrastrand  
 
Figure 3.  After entry into the nucleus, cisplatin preferentially forms covalent bonds to the 
nitrogen at position seven of purine bases.  There is a preference for GG adducts over AG 
adducts and intrastrand adducts over interstrand adducts. 
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guanines.  In all cases of binding, the ammine groups remain bound to the platinum.  It was 
found that there is a linear correlation between the amount of platinum bound to DNA and the 
level of cisplatin cytotoxicity (Fraval, 1979).  This result led researchers to explore the 
mechanisms by which cisplatin-induced nucleic lesions promote cell death.  The DNA adducts 
formed by cisplatin are known to affect DNA replication, but there is no correlation between 
cisplatin’s DNA synthesis inhibition and cytotoxicity (Sorenson, 1988).  The adducts cause 
distortions in DNA structure, namely bending and unwinding (Takahara, 1996).  Numerous 
signaling proteins recognize and bind to these structural distortions in the DNA, which initiates 
various signaling sequences that can lead to apoptosis (Chaney, 2004).  Formation of the 
platinum-DNA adducts does not invariably lead to cell death, as the adducts can be removed by 
DNA-repair pathways to repair the damage and promote cell survival.  Of the major DNA-repair 
pathways, nucleotide-excision repair (NER) plays the leading role in removing cisplatin-induced 
lesions, and its level of activity is inversely correlated with cytotoxicity (Ferry, 2000).  
Ultimately, the relative intensities of the pro-survival and pro-apoptotic signals initiated after 
cisplatin exposure are integrated to determine the fate of the cell. 
Resistance.  While cisplatin has had a major clinical impact, the main limitation on the drug’s 
utility has been the high rate of chemoresistance.  Despite the fact that patients consistently 
respond well to initial cisplatin treatment, resistance to the chemotherapeutic effects, i.e. 
induction of tumor cell apoptosis, often develops through several possible mechanisms (Galluzzi, 
2012) [Figure 4].  Cisplatin resistance can either be acquired during chronic drug treatment or 
can be an intrinsic tumor characteristic (Rabik, 2007), and researching cases of intrinsic 
resistance has helped produce a better understanding of the mechanisms of resistance to cisplatin 
in general.  Studies have shown that cisplatin resistance is mediated by two broad mechanisms: 
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first, a failure of enough cisplatin to 
reach the DNA; and, second, a failure 
of adduct formation to result in cell 
death.  In the first case, insufficient 
platinum DNA binding can be the 
result of decreased drug uptake 
(Holzer, 2006), increased drug efflux 
(Samimi, 2004), and/or increased 
levels of cytoplasmic thiol-containing 
species, such as glutathione, that bind 
to and inactivate the platinum center 
(Mistry, 1991).  In the second case, 
resistance mediated after DNA 
binding can be the result of increased removal of adducts from DNA or increased tolerance to the 
adducts.  As mentioned earlier, the main repair pathway for removing platinum-DNA adducts is 
NER, and resistance can occur in tumors with hyperactive NER due to factors such as increased 
activity of the endonuclease protein ERCC1 (Dabholkar, 1992).  Increased tolerance to the 
presence of the adducts can also occur through a decrease of DNA mismatch repair, bypassing of 
the adducts by polymerase ! and ", or a downregulation of apoptotic pathways (Kelland, 2007).  
Cisplatin-resistant tumor cells have often been known to display multiple mechanisms of 
resistance.  To combat resistance, clinicians are forced to administer very high doses of cisplatin.  
Unfortunately, however, the maximum dose is often not determined by the concentration of drug 
needed to eradicate the tumor, but instead is limited by severe systemic toxicity. 
Figure 4.  Mechanisms that can inhibit cisplatin-induced 
apoptotic signals and cause resistance in tumor cells 
(Siddik, 2003). 
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Dose-limiting Side Effects.  Administering the high doses of cisplatin that are necessary to 
counteract resistance can lead to severe systemic toxicity, because cisplatin, like all 
chemotherapy drugs, kills both cancerous and healthy cells.  Cisplatin’s side effects have been 
called “notorious,” and it has been questioned whether its use would have been continued to be 
approved if not for the development of several co-treatments, such as prehydration, to ameliorate 
the unwanted toxicities (Borch, 1989).  The most clinically relevant and dose-limiting side effect 
is nephrotoxicity, defined as damage to the kidneys (Arany, 2003).  The nephrotoxicity may in 
part be explained by the fact that the kidney accumulates and retains more cisplatin than all other 
organs and is the main excretory organ for the injected drug (Litterst, 1977).  Cisplatin is mainly 
taken up by the proximal tubule and distal cells of the nephron, and the apoptosis and necrosis it 
causes there can produce severe and potentially irreversible renal failure (Miller, 2010).  
Cisplatin also frequently causes peripheral neuropathy and myelosuppression, as well as 
occasional gastrointestinal toxicity (Rabik, 2007).   
 Ototoxicity, defined as damage to the hearing or balance functions of the ear, is another 
serious dose-limiting side effect that occurs in up to 80% of patients treated with cisplatin 
(Knight, 2007).  Research suggests that children are even more susceptible to cisplatin-induced 
ototoxicity than adults (Li, 2004).  Cisplatin’s ototoxicity is caused by the death of 
mechanosensory hair cells in both the inner and outer ear (Cardinaal, 2000).  Mechanosensory 
hair cells transduce physical vibrations into neurological impulses that allow organisms to hear, 
and their death is the cause of at least 75% of human deafness (Hawkins, 2004).  Although 
various mechanisms have been proposed for how cisplatin damages hair cells, evidence suggests 
that the drug triggers the production of reactive oxygen species (ROS) that can trigger cell death 
(Rybak, 2007).  While multiple protective treatments are being explored (Rybak, 2009), there is 
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currently no effective way to prevent cisplatin-induced ototoxicity.  The severe systemic toxicity 
caused by cisplatin limits clinicians’ ability to administer large enough doses of the drug to 
successfully eradicate tumors before inducing resistance. 
Beyond Cisplatin 
Next-generation Platinum Drugs.  Cisplatin’s spectacular cytotoxic action but high prevalence 
of resistance and undesirable suite of side effects spurred researchers to develop derivatives with 
decreased toxicity (Anderson, 2012).  Since cisplatin came to the market in the late 1970s, 
countless similar compounds have been synthesized and tested for anti-cancer activity, but only 
carboplatin and oxaliplatin have been approved in the U.S. as additional platinum-based 
chemotherapy drugs.  The next generation platinum drugs were designed based on the hypothesis 
that replacing the chlorides with a more stable leaving group might reduce the toxicity without 
affecting the chemotherapeutic effect (Kelland, 2007) [Figure 5].  While carboplatin and 
oxaliplatin have comparable cancer killing effects and somewhat reduced toxicity in comparison 
to cisplatin, the slight increases in drug efficiency came with vast increases in price (Lokich, 
1998; Jung, 2007).  Thousands of platinum compounds have been developed and tested for 
chemotherapeutic activity, but none have been found to confer significant advantages over 
cisplatin, carboplatin, and oxaliplatin (Eckardt, 2009; Kelland, 2002).   
Figure 5.  Structural comparison of the three Pt chemotherapy drugs approved by the FDA.   
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The lack of success in the cisplatin derivatives is truly incredible in light of the fact that the 
seminal compound was stumbled upon completely by chance.   
 The inability to make more efficient platinum-based chemotherapy drugs led researchers 
to explore a century-old concept that seemed like pure science fiction when first proposed.  In 
1911, Paul Ehrlich, a Noble Prize-winning German physician and researcher who has been called 
the “father of chemotherapy,” proposed the idea of a “magic bullet,” which is a theoretical 
compound that could be made to selectively target disease-causing cells (Strebhardt, 2008).  If a 
“magic bullet” could be used to deliver chemotherapy drugs directly to tumors, then there would 
no longer be any need to worry about off-target side-effects, because the drug would only be 
available for action at the intended target.  Much research has been done to develop a system that 
can specifically target drug delivery to cancer cells, and progress in this area is accelerating.  
Molecularly-targeted Drug Delivery.  One area of research has focused on conjugating cisplatin 
and other chemotherapeutic drugs to species whose biological characteristics favor their 
accumulation in tumor cells.  When attempting to target cytotoxic action, researchers looked 
inward and took a page out of the immune system’s playbook by using antibodies to target drug 
payloads to tumor cells (Scott, 2012).  The goal of such work has been to combine the cell killing 
activity of cytotoxic agents, which often display little selectivity, with the antigen-specific 
affinity of monoclonal antibodies.  While this approach sounds very promising in theory, in 
practice it is hampered by the fact cancer cells have evolved with a selection pressure to not 
express surface proteins that will mark them as foreign to the immune system (June, 2012).  
There are particular cases in which individual patients have tumor-specific antigens, but there is 
much debate as to whether the extreme cost of developing personalized antibody treatments, 
which still have concerns about poor efficacy, for these individuals is worth the short increase in 
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lifespan that the treatments might afford (Maeda, 2012).  Efforts have also been made to 
conjugate cisplatin to antibodies that bind to proteins specifically expressed on tumor 
vasculature, such as vascular endothelial growth factor (VEGF) (Ko, 2008); however, results 
have indicated that such a treatment would only benefit an extremely small subset of patients.  
These results are especially discouraging for the future of antibody-targeted chemotherapy drug 
delivery, because tumor vascular cells are known to have far more distinct surface protein 
expression than tumor cells themselves do (Ruoslahti, 2010).  There are examples of patients 
with rare variants of particular cancers responding better to cisplatin-antibody conjugates than to 
the free drug alone, but this does not appear to be the case for a large percentage of the patient 
population (Pegram, 1998).  In summary, attempts to molecularly target cisplatin and other 
chemotherapy drugs to tumor cells have largely been disappointing (Cleeland, 2012), and 
researchers are still searching for alternate methods to target chemotherapeutics.   
Enhanced Permeability and Retention Effect.  ‘Passive’ targeting is an alternative approach to 
directly delivering drugs to tumor cells that takes advantage of the fact that most solid tumors 
have unique microenvironments that are not observed in normal tissues.  In contrast to ‘active’ 
targeting techniques, such as antibody conjugation, passive targeting methods exploit tumor-
specific characteristics that are far more universally valid than any particular molecular markers 
(Torchilin, 2011).  The practice of passively targeting of drugs to tumors was first developed by 
Jaspanese researcher Hiroshi Maeda over 25-years-ago.  The Maeda lab discovered that 
macromolecules and macromolecular drugs (i.e. nano-sized) delivered into the blood accumulate 
preferentially in tumor tissues, reaching significantly higher concentration than in the plasma or 
other organs (Maeda, 1984).  After observing the tumoritropism of macromolecular drugs, the 
Maeda lab determined that this altered biodistribution is the result of abnormalities of tumor 
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vasculature that make the endothelial lining of the blood vessel wall more permeable relative to 
vasculature of other tissues (Matsumura, 1986).  Tumor vasculature is comprised of 
disorganized, poorly aligned endothelial cells with wide fenestrations up to 4 µm, which is vastly 
wider than in normal vasculature (Farnsworth, 2013).  Tumor vessels also have a wide lumen 
and lack a smooth muscle layer, both of which contribute to the hyperpermeability in tumor 
tissues (Greish, 2010).  In addition, tumor cells hyperproduce vascular mediators, such as VEGF 
and bradykinin, that also enhance vascular permeability (Fang, 2003).  The combination of these 
vasculature alterations allows macromolecules, including nanoparticles, to permeate far more 
efficiently from plasma into tumors than into other tissues and organs (Iyer, 2006).  Additionally, 
the lack of a functional lymphatic drainage system in most solid tumors means that 
macromolecules are retained in the tumor for up to weeks (Dreher, 2006).  The Maeda group 
dubbed this altered biodistribution seen in cancer patients, which results from the unique nature 
of tumor vasculature and lymphatics, the Enhanced Permeability and Retention (EPR) effect 
[Figure 6].  In addition to altering biodistribution, the EPR effect also increases the plasma  
Figure 6.  Schematic depiction of the vascular deformities in and around tumor tissue that cause 
the EPR effect and tumoritropism of nanoparticles (Dand, 2013). 
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half-life of nano-size drugs, because their size exceeds the limit of renal excretion threshold 
(Greish, 2010).  Since its initial description, the EPR effect has become one of the few tumor-
specific characteristics that is a “gold standard” for antitumor drug delivery with minimized off-
target effects (Maeda, 2000). 
Gold Nanoparticles (AuNPs) for Drug Delivery 
Desirable Characteristics of AuNPs.  Nanomaterials are frequently conjugated to anticancer 
drugs for the purpose of selectively targeting non-macromolecular drugs to tumor via the EPR 
effect.  The nanomaterials most often used as delivery vehicles include polymers (Maeda, 1984), 
dendrimers (Svenson, 2009), liposomes (Maruyama, 2011), and nanoparticles (NPs) of various 
shapes and sizes (Ghosh, 2008).  In the past decade, gold nanoparticles (AuNPs) have emerged 
as a promising candidate for the delivery of drug payloads to solid tumor targets (Paciotti, 2004).  
AuNPs have a variety of unique chemical and physical properties that make them very attractive 
for use as drug delivery systems (DDS) to exploit the EPR effect.  First, AuNPs are easily 
synthesized in a wide range of shapes and sizes and with a high degree of size monodispersity 
(Bastus, 2011), the later of which is especially important for developing a reproducible 
treatment.  Once synthesized, AuNPs are readily functionalized through thiol linkages that use 
notoriously strong gold-sulfur interaction (Hakkinen, 2012).  Thiol linkages are often used to 
create self-assembled monolayers (SAM) of organic molecules on gold surfaces (Love, 2005).  
The purpose of an SAM is to anchor a molecule with a functional end group to a substrate via a 
different functional head group that possesses a strong affinity for the substrate [Figure 7].  The 
functional end group at the end of the SAM tail can be used to bind other molecules that would 
otherwise be unable to bind to the substrate directly, and through this mechanism the surface of 
AuNPs can be functionalized with an incredible diversity of molecules (Woehrle, 2005).  In 
 19 
addition, AuNPs have distinctive optical properties due to their localized surface plasmon 
resonance (SPR) at approximately 520 nm that allow for optical characterization (Haiss, 2007).  
 
 
While characteristics related to synthesis and characterization should be taken into account when 
designing a DDS to reduce the toxicity of a treatment it, it is of paramount importance that 
delivery vehicles do not have significant toxicity themselves.  
Toxicity of AuNPs.  The toxicity of AuNPs is an area of avid research, as fears about 
nanoparticles’ potentially toxic side effects are one of the major factors slowing their progression 
to mainstream clinical use.  One thing that has been made clear by initial research on 
nanoparticle toxicity is that toxic side effects are dependent on both the concentration and 
chemical identity of the nanoparticles being tested (Braydich-Stolle, 2005).  Bulk gold has long 
been used for medicinal purposes, including treating arthritis, but NPs are known to exhibit 
different properties from their bulk counterparts and much research is going into the cytotoxicity 
of AuNPs (Lim, 2011).  So far, the majority of the research has shown that AuNPs have minimal 
toxicity, which has been found to depend on factors such as size, concentration, exposure time, 
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Figure 7. Structural depiction of SAM components.   
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and surface functionality (Mironava, 2011; Bozich, 2014).  Two seminal in vitro studies found 
that AuNPs are taken up by human cells, but that this uptake does not result in cellular toxicity 
(Connor, 2005; Chithrani, 2006).  The results of other in vitro and in vivo studies have, on the 
other hand, produced decidedly mixed results.  A study using human dermal fibroblasts found 
that incubation with AuNPs for six days caused an increase in apoptosis that was at least partially 
due to decreased expression of extracellular matrix proteins; however, their data also indicates 
that the cellular damage is not permanent and that cells can completely recover (Mironava, 
2011).  An in vivo mouse study found no evidence of toxicity after repeated intraperitoneal (i.p.) 
administration of 13 nm AuNPs (400 #g/kg/day) every day for eight days, even though all of the 
organs tested, including the brain, showed NP accumulation (Lasagna-Reeves, 2010).  A 
different mouse study found that i.p administration of AuNPs of various sizes (8 mg/kg/week) 
for three weeks resulted in severe toxicity and lethality for mice exposed to AuNPs from 8 to 37 
nm, but did not show harmful effects with AuNPs of 3, 5, 60, and 100 nm (Chen , 2009).  The 
dearth of published studies on AuNPs toxicity and the lack of consistency of previous findings 
necessitates more research being done in this area.  Still, there are a few specific examples of in 
vivo studies that suggest that AuNPs can effectively be used as drug delivery vehicles without 
inducing toxic side effects. 
AuNP-Cisplatin Conjugate Synthesis.  Recent research focusing on the vehiculation of cisplatin 
with AuNPs has provided very encouraging results.  Cisplatin’s potent cytotoxic action but 
severe multiorgan toxicity profile makes it a perfect candidate for conjugation to nanoparticles.  
The use of AuNPs as a DDS for cisplatin was first proposed by Vazquez-Campos et al. as a 
means to increase the concentration of drug inside malignant tumor cells relative to healthy cells, 
and therefore reduce toxic side effects (Vazquez-Campos, 2008).  Since the initial proposal of 
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AuNP-cisplatin conjugates, one research group non-covalently conjugated cisplatin onto 
hydrophilic assemblies of AuNPs-L-Aspartate nanostructures, and in in vitro tests found that the 
conjugates led to an increased susceptibility of cancer cells to treatment relative to free cisplatin 
alone (Tomuleasa, 2012).  However, it is unlikely that Tomuleasa et al.’s results would translate 
to in vivo testing, as a comparison of the release of electrostatically-bound versus covalently-
bound cisplatin from conjugates in the presence of serum showed that non-covalently-bound 
cisplatin conjugates are significantly less stable in physiological media (Comenge, 2010).  It is 
critical that cisplatin remains bound to its delivery vector in physiological media, because release 
prior to entry into tumor cells would prevent the drug from exploiting the EPR effect as a 
conjugate.  Comenge et al. developed a system in which AuNPs are first functionalized with 
mercaptoundecanoic acid (MUA) to create a SAM with carboxylic terminal groups, which is 
then reacted with cisplatin to form a coordination bond between the drug and the AuNPs 
(Vazquez-Campus, 2008) [Figure 8].
 
Figure 8.  AuNP-cisplatin conjugate synthetic scheme, adapted from (Vazquez-Campus, 2008). 
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The key aspect of the covalent MUA-cisplatin bond is that the link is pH sensitive: at serum pH 
(~7.4) the coordination bond between the linker molecule and the drug is stable, but decreasing 
the pH (<5) leads to hydrolysis of the MUA-Pt bonds (Comenge, 2012).  NPs are well known to 
be internalized via endocytic pathways (Nel, 2009) (Figure 9), and the decreasing pH within 
 
Figure 9.  Different endocytic pathways by which NPs are internalized (Research at Dordick J. 
S. Group).  After uptake into endosomes, NP cargo must escape the endosome to reach the target 
of its cytotoxic action, which in the case of cisplatin is the nucleus. 
 
endosomes, especially late endosome and lysosome, promotes the release of cisplatin after 
internalization via protonation of the MUA carboxylic group.  After release from AuNPs, 
cisplatin is able to escape the endosome and perform its cytotoxic action in the nucleus.  By 
combining exploitation of the EPR effect to have AuNPs preferentially transport cisplatin to 
tumor cells and a pH sensitive coordination bond to promote drug release upon uptake by tumor 
cells, Comenge et al. were able to develop a “magic bullet” cisplatin delivery system. 
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AuNP-Cisplatin Conjugate Testing.  After developing the AuNP-cisplatin conjugates, Comenge 
et al. showed in both in vitro and in vivo experiments that the conjugate design has significant, 
positive effects on cisplatin’s pharmacokinetics, biodistribution, and toxicity (Comenge, 2012).   
The researchers performed assays to quantify the Pt cell internalization and DNA accumulation 
in human lung carcinoma derived cell line A549 cells after treatment with free cisplatin or 
AuNP-cisplatin conjugates for up to 24 hours.  Faster cellular uptake and higher cytoplasmic 
levels of Pt were found for the conjugate-delivered drug, which resulted in up to 125 times 
higher levels of Pt found in the DNA at 24 hours.  The increased rate of uptake can be explained 
by the fact that AuNP-cisplatin enters cells via an active endocytic mechanism, as opposed to the 
passive diffusion and some active transport of free cisplatin into cells (Jung, 2007).  The rapid 
accumulation of cisplatin in cells via endosomal uptake when delivered by AuNPs may help 
overcome resistance mechanisms that involved overexpression of cisplatin efflux proteins or 
underexpression of uptake proteins (Xue, 2013).  
 After proving that AuNPs-cisplatin conjugates have greater cellular uptake and better 
DNA targeting in in vitro experiments, the researchers tested the ability of the nanocarrier in 
comparison with free cisplatin to treat a mouse model of cancer.  Tumor-bearing Severely 
Compromised ImmunoDeficient (SCID) mice were treated with two i.p. injections of saline, free 
cisplatin, or AuNP-cisplatin (1.5 mg/kg).  It was found that nanoconjugation significantly 
reduced cisplatin-induced system toxicity and nephrotoxicity, as shown by tracking mouse body 
weight changes and histological studies of the kidney respectively, without affecting therapeutic 
benefit, as measured by tumor growth suppression.  The finding of a clear reduction in 
nephrotoxicity is especially important, because nephrotoxicity is considered to be the dose-
limiting factor in cisplatin treatment.  The consistently positive results of the in vitro and in vivo 
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tests performed by Comenge et al. are very encouraging, and they show the need for future 
studies to further investigate whether AuNP conjugation is able to remove the toxic side effects 
of cisplatin while maintaining its therapeutic benefits.  Currently, their mouse study is the only 
published in vivo study investigating the effects of AuNP-cisplatin conjugates.   
Zebrafish Model 
 Zebrafish (Danio rerio) have emerged as useful and cost-effective model organism for in 
vivo testing that combines the scale and throughput of in vitro assays with the systems 
physiology of  animal studies.  Zebrafish offer many advantages as a model organism including a 
fully-sequenced genome and relative genetic homology with humans, well-characterized mutant 
strains, large number of offspring, rapid embryonic development, embryonic transparency, low 
upkeep costs, and the ability to absorb drugs dissolved in liquid media (Zon, 2005).  The 
feasibility of using zebrafish to study the response of organisms to AuNPs and their derivatives 
has been demonstrated by various research groups.  It was found that zebrafish embryos raised 
from 5 hours post-fertilization (hpf) to 120 hpf in AuNP solution showed no toxic  side effects at 
any of the sizes of AuNPs tested (Bar-Ilan, 2009).  Another research group found that the 
diffusion of AuNPs in zebrafish embryos led to slight, but not significantly different from the 
control, stochastic toxic effects, and concluded that AuNPs are biocompatible with zebrafish 
(Browning, 2009).  While the results of these studies are promising, a different study showed that 
zebrafish embryos raised from 5 to 120 hpf in 1.5 nm AuNPs had significantly lower 
survivorship into adulthood and persistent behavioral deficits relative to controls (Truong, 2012).  
The lack of many research articles about AuNP zebrafish toxicity is compounded by the fact that 
the existing articles vary greatly in factors such as nanoparticle size and treatment time, and there 
is a need for more comprehensive studies to address the toxicity of AuNPs to zebrafish.  
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However, accessible evidence certainly does not rule out the possibility of performing tests 
involving AuNPs in zebrafish. 
 The use of zebrafish in pharmacological toxicology studies is becoming increasingly 
common, and is even being adopted by the pharmaceutical industry (Fleming, 2013).  In fact, 
zebrafish are frequently used as a model to study cisplatin-induced ototoxicity (Ton, 2005; Ou, 
2007; Vlastis 2012; Thomas, 2013).  Zebrafish, along with all other fish and amphibians, express 
neuromasts- bundles of mechanosensory hair cells- along the sides of their bodies in a sensory 
system called the lateral line, which is closely related, and probably ancestral, to the human 
auditory system (Dambly-Chaudiere, 2003).  The zebrafish lateral line is frequently used to study 
hair cells due to its easy access in comparison to the inner ear and its genetic homology relative 
to the human auditory system.  Cisplatin is known to cause auditory impairment in cancer 
patients by killing mechanosensory hair cells in the inner ear, and it has also been shown to kill 
zebrafish lateral line hair cells in a dose-dependent manner (Ou, 2007).   
 Various mechanisms have been proposed for how cisplatin damages hair cells once inside 
the cell, including triggering oxidative stress (Ravi, 1995); however, until recently the 
mechanism of cisplatin uptake into hair cells was unknown.  Efforts to prevent cisplatin-induced 
ototoxicty hinge on the development of a deeper understanding of the mechanisms through 
which this toxicity occurs.  While transporter proteins Ctr1 and Oct2 have been demonstrated to 
play leading roles in cisplatin uptake into cancer cells, it was recently demonstrated that 
cisplatin-induced zebrafish lateral line hair cell death is dependent on the activity of 
mechanotransduction (MET) channels (Thomas, 2013).  This finding strongly suggests that 
cisplatin enters hair cells through the MET channel, and that cisplatin-induced ototoxicity is 
dependent on that entry phenomenon.  If this were the case, then it is likely that cisplatin-induced 
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ototoxicty could be reduced, if not prevented, by conjugation of the drug to a material, such as 
AuNPs, that is too large to fit through the MET channel, which has a diameter of approximately 
1.2 nm (Fettiplace, 2009) [Figure 10].   
 
Figure 10.  Hypothesized mechanism by which conjugation to AuNPs could reduce cisplatin’s 
ototoxocity.  Once nanoconjugated, the effective size of drug is too large to fit through the MET 
channel and enter hair cells. 
 
AuNP-Cisplatin Conjugate Testing in Zebrafish 
 The goal of this study was to use larval zebrafish as an in vivo model to investigate 
whether conjugation to AuNPs reduces, if not eliminates, cisplatin’s ototoxicity.  Comenge et al. 
have already demonstrated that AuNP-cisplatin conjugates retain the free drug’s cancer cell 
killing ability while significantly reducing its nephrotoxicity and systemic toxicity.  The potential 
utility of AuNPs as cisplatin drug delivery systems would be greatly supported by evidence that 
nanoconjugation reduces the drug’s ototoxicity.  The existing studies of AuNPs zebrafish 
toxicity, and AuNPs toxicity in general, have provided inconsistent results, so it is crucial that 
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more research is done on this subject.  While AuNP-cisplatin conjugates were shown to be non-
toxic to mice, it would be very significant to find that they are also non-toxic to a different model 
organism.  The results of in vivo testing of AuNP-cisplatin conjugates with zebrafish larvae 
should provide information about the feasibility of using nanoconjugation to reduce ototoxicity, 
as well as about the general toxicity of high concentrations of AuNPs to zebrafish.  
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Experimental Methods 
Synthesis of MUA-Capped Gold Nanoparticles.   
Synthesis of Gold Seeds.  AuNPs were synthesized according to a seeded growth strategy 
developed by Bastus et al. that is based on the reduction of gold salt by citrate (Bastus, 2011).  
Prior to synthesis, all glassware was thoroughly cleaned with acetone, rinsed in DI H2O, and 
dried with pressurized air to help prevent unwanted nucleation and aggregation of AuNPs during 
the synthesis.  A spatula fashioned from a plastic straw was used to transfer gold(III) chloride 
(Sigma Aldrich) due to the compound’s tendency to plate to other metals, and, before use in 
synthesis, the gold(III) chloride solution was syringe filtered using a 0.2 #m PTFE filter.  Gold 
seeds were synthesized by using a micropipette to add 1 mL of 25 mM gold(III) chloride (AuCl3) 
solution to a boiling solution of 150 mL of 2.2 mM sodium citrate dibasic sesquihydrate (Sigma 
Aldrich) in a 250 mL Erlenmeyer flask.  The liquid was heated on a Corning hot stir plate and 
strongly stirred (stir setting = 5.5) by a 1” Teflon-coated magnetic bar.  No reflux condenser was 
used with the goal of avoiding the presence of temperature gradients in the liquid that would 
result in uneven nanoparticle growth (Kimling, 2006).  Upon addition of the gold, the color of 
the solution changed from colorless to yellow to bluish purple to pinkish red within three 
minutes.  The reaction was allowed to run at 100 ºC for 10 minutes.  Then, the temperature was 
decreased to 90 ºC and 2 mL of the solution were extracted via a Pasteur pipette for 
characterization by scanning electron microscopy (SEM) and UV-vis spectroscopy.   
Seeded Growth of AuNPs.  When the gold seed solution reached 90 ºC, 1 mL of 60 mM sodium 
citrate and 1 mL of 25 mM gold(III) chloride solutions were added by micropipette with a time 
delay of 2 minutes.  After 30 minutes, another aliquot of 2 mL of the nanoparticle solution were 
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extracted for further characterization.  By repeating this process of the sequential addition of 
sodium citrate and gold(III) chloride followed by a 30 minute reaction period, AuNPs of 
progressively larger sizes were grown.  Six iterations of the sequential addition process were 
performed, and aliquots of the seven different AuNP solutions (including the seeds) were 
characterized by SEM and/or UV-Vis spectroscopy.  After characterization of the AuNPs grown 
by the different number of seeded-growth steps, nanoparticles produced by 2 and 3 growth steps 
were selected for use in the rest of the study. 
Conjugation of MUA and Concentration of Functionalized AuNPs.  The conjugation of 11-
Mercaptoundecanoic acid (MUA) (Sigma Aldrich) was performed based on the procedure 
developed by Comenge et al. (Comenge; 2010, 2012).  2.2 mL of 10 mM MUA basic solution 
were added to 50 mL of AuNP solution in a 125 mL Erlenmeyer flask and the solution was 
stirred gently (stir setting = 2, 1” Teflon-coated stir bar) overnight.  The MUA solution required 
heat with stirring for 10 minutes and heated sonication for 15 minutes to fully dissolve the solid, 
and was basified with 7.5 #L of 2M NaOH per mL solution.  Before addition to the AuNPs, the 
MUA solution was syringe filtered using a 0.2 #m PTFE filter.  The MUA-solution was made 
fresh before each conjugation, because the thiol compound begins to aggregate and precipitate if 
left in solution for longer than a week.  50 mL of the MUA-AuNP conjugate solution formed 
overnight were decanted into a 50 mL centrifuge tube and centrifuged for 2 minutes at 2500 rcf.  
The quick centrifugation caused floating chunks of excess MUA to form a pellet, and the 
supernatant was decanted into another 50 mL centrifuge tube.  2.5 mL of a 200 mM, pH = 2.6 
glycine (Sigma Aldrich)/ HCl buffer were then added to the 50 mL of MUA-capped AuNPs to 
destabilize them by protonation of the carboxylic acid functionality of the MUA self-assembled 
monolayer.  The destabilized solution was then centrifuged for 30 minutes at 2500 rcf, the 
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supernatant was removed, and the nanoparticle pellet, which was actually more of a gel, was 
resuspended in 1 mL of 50 mM, pH = 8 tricine (Sigma Aldrich) buffer.  It was critical that the 
centrifuge used was of swinging bucket style rather than fixed-angle style because the latter led 
to the accumulation of nanoparticles on one wall of the centrifuge tube, which prevented removal 
of the supernatant without disturbing the pellet and therefore decreasing the magnitude of 
concentration.  The excess MUA that had not been removed by differential centrifugation was 
removed from the concentrated MUA-AuNP solution by a dialysis step ($500, overnight) using 
50 mM, pH = 8 tricine buffer as the solvent and membrane tubing with a 3.5 kDa pore size, 
which is larger MUA but smaller than the AuNPs. 
Gold Nanoparticle Characterization Techniques.  
UV-Vis Spectroscopy.  UV-visible spectra were acquired with an Agilent 8453 UV-Vis 
spectrophotometer.  AuNP solutions (160 #L) were placed in a quartz Precision Cells Type 
703M sub-micro cuvette with a 10 mm path length, and the spectral analysis was performed in 
the 200 to 1000 nm range at room temperature with a resolution of 1 nm.  If the maximum 
absorbance (absmax) of the solution was greater than 2 AU, then the sample was diluted so that 
the absmax was less than 2 AU.  Citrate-capped AuNPs were diluted with DI H2O (Narayanan, 
2008), while concentrated MUA-capped AuNPs and AuNPs-cisplatin conjugates were diluted 
with 50 mM, pH = 8 tricine buffer.  At the beginning of every analysis session, a background 
spectrum was collected with the cuvette containing 160 #L of DI H2O.  In between each 
individual sample analysis the cuvette was rinsed with DI H2O, dried with pressurized air, and 
the outside was wiped with KimWipes.  To facilitate comparison, all spectra were normalized to 
400 nm (Rodriguz-Fernandez, 2006) 
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Scanning Electron Microscopy.  AuNPs synthesized using the seeded-growth strategy were 
visualized using a TESCAN MIRA3 SEM operating at an accelerating voltage of 20.0 kV.  
Samples were prepared by pipetting 1#L droplets of the AuNP solutions onto copper tape and 
leaving them to dry in the air for at least two hours.  The SEM images of the AuNPs were used 
for determining the size distribution and shape of the particles.  For each sample analysis, a 
representative image was selected and the size of 100 particles was measured using ImageJ, 
which allowed for the calculation of the average size and standard distribution of the AuNPs. 
Synthesis of Aquated Cisplatin [Pt(H2O)2(NH3)2](NO3)2.   
 
 The synthesis of aquated cisplatin was performed based on the procedure used by 
Comenge et al. (Comenge, 2012) [Figure 11].  An aqueous silver nitrate solution was prepared 
by dissolving 169 mg (1 mmol) AgNO3 (Sigma Aldrich) in 2.5 mL of DI H2O.  The AgNO3 
solution was added dropwise using a Pasteur pipette to a suspension of 150 mg (0.5 mmol) 
cisplatin (Sigma Aldrich) in 2.5 mL DI H2O in a 25 mL Erlenmeyer flask.  Upon the addition, 
AgCl precipitated and the yellow color of the initial mixture began to disappear.  The resulting 
suspension was heated to 50 ºC for 1 hour on a hot stirring plate.  During this time, the reaction 
was shielded from light under a cardboard box, because light can initiate the conversion from 
cis-[Pt(H2O)2(NH3)](NO3)2 to trans-[Pt(H2O)2(NH3)](NO3)2 in solution (Wagstaff, 2012).  When 
the reaction was complete the solution was a milky white, and the precipitated AgCl was 
removed by centrifugation at 3000 rcf for 15 minutes.  The collected supernatant solution was 
syringe filtered using a 0.2 #m PTFE filter and evaporated to dryness on the rotovap in a 50 mL 
round bottom flask.  The resulting light yellow, grayish residue (76±4% (mean±SD)) was further 
dried under high vacuum to afford a powder of the same color for further use and 
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characterization: Melting range (Recorded on Optimelt MPA100 with 1 ºC/min heating) = 177.8-
181.3 ºC ; FTIR (neat) 3309, 3237, 1481, 1339, 1275, 1185, 1140, 999 cm-1 [Figure S3].  
 
Figure 11.  Depiction of the reaction performed to synthesize aquated cisplatin.  Bellow the 
structure of the starting material and the product are photographs of their appearance. 
 
Conjugation of Aquated Cisplatin to MUA-Capped AuNPs 
 The conjugation of aquated Cisplatin to MUA-Capped AuNPs was performed based on 
the procedure developed by Comenge et al. (Comenge, 2012).  5 #L of 16 mg/mL 
[Pt(H2O)2(NH3)2](NO3)2 aqueous solution were added to 1 mL of concentrated MUA-capped 
AuNPs suspended in 50 mM tricine buffer in a 1 Dram glass vial.  The glass vials were used as 
reaction vessels because their small diameter allowed the minute volume of solution to reach a 
sufficient depth for a stir bar to be used.  The solution was stirred minimally (stir setting = 1, 
0.25” Teflon-coated stir bar) for 25 minutes, and then the reaction was stopped by removing the 
excess aquated cisplatin by dialysis ($500, overnight) using 50 mM, pH = 8 tricine buffer as the 
solvent and membrane tubing with a 3.5 kDa pore size.  Quantification of cisplatin loading onto 
the AuNPs was performed using inductively coupled plasma optical emission spectrometry (ICP-
OES).   
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ICP-OES Analysis of AuNPs-cisplatin Samples  
 ICP-OES data were obtained using a Teledyne-Leeman Labs Prodigy PS-1000 ICP 
spectrometer (Tufts University Department of Chemistry).  Prior to analysis, both nanoparticle 
samples and standards were digested with 0.2 M nitric acid to avoid potential precipitation of 
metal salts, and a solution of 0.2 M nitric acid was used to collect a baseline reading.  Samples of 
50 mL of each standard and 5 mL of each nanoparticle solution were prepared.  Nanoparticle 
solutions were diluted 1:50 to afford a large enough volume for analysis.  Both platinum (195Pt) 
and gold (197Au) concentrations were measured.   
 Calibration standards were prepared containing both platinum and gold by serial dilutions 
of 1000 ppm platinum stock ICP solution and 1000 pm gold stock ICP solution (Fluka) in 0.2 M 
nitric acid.  The calibration standards contained: 0.025 ppm Pt and 0.25 ppm Au; 0.05 ppm Pt 
and 0.5 ppm Au; 0.2 ppm Pt and 2.0 ppm Au; 1.0 ppm Pt and 10.0 ppm Au; 2.0 ppm Pt and 20.0 
ppm Au; 10.0 ppm Pt and 100.0 ppm Au.  A 10.0 ppm solution of manganese was used as an 
internal standard to align the detector to the most intense portion of the plasma.  Also, a 10.0 
ppm solution of each element of interest was used to align the spectrometer to the most intense 
portion of the emission line for each element.  The emission lines selected for each element were 
as follows: Pt = 214.423 nm; Mn = 257.610 nm; Au = 242.795 nm.  Whenever a sample was not 
actively being run, DI H2O was aspirated through the plasma.   
 After alignment of the detector, the ICP was calibrated using the standard solutions.  
Then, ICP-OES analysis of elemental concentrations in each of the nanoparticle sample solutions 
was performed.  Instrument operating conditions used were RF power of 1.2 kW, 18 L/min 
coolant flow, 0.0 L/min auxiliary flow, and 32 PSI on the nebulizer.  The spectrometer was kept 
at 34 ºC, on low purge, and with an axial view of the plasma.  The solution uptake rate was 1.4 
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mL/min, and a 40 second delay was programmed between beginning of sample uptake and start 
of emission recoding.  The integration time was 10 seconds, and three integrations were 
performed per sample.   
Zebrafish Strains and Husbandry 
 Zebrafish (Danio rerio) embryos of either sex were produced by matings of adult fish 
maintained on a 14:10 light-cycle in system water at 28.5 °C with pH ranging from 7.0-7.4 in the 
Bard College Biology Department zebrafish facility.  All of these conditions are standard in 
zebrafish research (Lawrence, 2007).  The adults used for mating were either Et4xTU/TL or 
Et20xTU/TL transgenic strains, so the offspring produced were either pure TU/TL or carriers of 
one of the two transgenes.  Et4 transgenic zebrafish express green fluorescent protein (GFP) in 
hair cells of the lateral line (Lopez-Schier, 2006), and Et20 transgenic zebrafish express GFP in 
the neuromast supporting cells (Moon, 2011).   
 For matings, between 1-2 male and 2-3 female adult fish were placed together in a mating 
tank with fake vegetation during the day, and the next morning after 10 AM embryos were 
collected and sterilized in 0.5% bleach solution (Bates, 2006).  Embryos were maintained in the 
zebrafish facility at densities of 20-50 animals per 100 mm2 Petri dish in 28 °C 0.5$ E2 media 
(7.5 mM NaCl, 0.25 mM KCl, 0.5 mM MgSO4, 75 #M KH2PO4, 25 #M Na2HPO4, 0.5 mM 
CaCl2, 0.35 mM NaHCO3, 0.5 mg/L methylene blue).  E2 media was changed daily, and larvae 
older than 4 days post fertilization (dpf) were fed once daily with micro powder food.  At 3 dpf, 
larvae were imaged using fluorescence microscopy to observe GFP expression so that they could 
be sorted according to genetic strain.  Et4 larvae were desired for use in the in vivo assays due to 
the easy imaging of their hair cells, but larvae of all strains had to be used as a result of the 
dearth Et4 embryos produced. 
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Ototoxicity Assay 
 To assess ototoxicity, 5 dpf zebrafish larvae were treated for 24 hours with test 
compounds that were dissolved in 50 mM, pH = 8 tricine buffer.  The protocol was based on an 
established hair cell ablation procedure that involves treating zebrafish larvae in 50 #M cisplatin 
for 24 hours (Ton, 2005).  Test compounds were dissolved in the tricine buffer instead of E2 
media because the AuNP-cisplatin conjugates were suspended in tricine buffer, and keeping the 
solvent constant between treatment groups helped to control variance between the treatment 
conditions.  Treatment conditions included 50 #M cisplatin, 20 #M cisplatin, 7 #M cisplatin, 
AuNP-cisplatin solution with 20 #M cisplatin, and 50 mM, pH = 8 tricine buffer as a control.  
For each treatment, between 3 and 6 larvae were used, and the small sample sizes were due to 
difficultly producing embryos in large numbers.  For each treatment group, all of the larvae were 
placed into a well in a 24-well plate containing 1 mL of the particular treatment solution.  At the 
end of drug treatment, the 6 dpf larvae were washed in E2 media (3$, 2 min), and their surviving 
lateral line hair cells were counted by fluorescence microscopy.  The percentage of surviving 
hair cells following treatment was calculated relative to the tricine buffer controls.       
Fluorescence Microscopy Imaging                                                                               
 The purpose of fluorescence imaging was to visually assess larval zebrafish hair cell 
integrity after exposure to cisplatin in the free form and conjugated to AuNPs.  Due to the fact 
that all in vivo experiments were performed with a mixture of Et4, Et20, and  
TU/TL zebrafish larvae (not all of which expressed GFP in hair cells), the hair cells of all larvae 
were selectively labeled prior to imaging.  All of the fish in each treatment group were labeled 
simultaneously and subsequently imaged individually.  For vital labeling of hair cells, zebrafish 
larvae were immersed in a 50 #M solution of 4-(4-diethylaminostyryl)-1-methylpyridinium 
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iodide (DiASP, Sigma Aldrich) for three minutes at room temperature in the dark (Faucherre, 
2009).  The working DiASP solution 
was freshly prepared before each use 
from a 1 mg/mL stock stored in the 
freezer.  Stained larvae were washed 
briefly in E2 media (3$, 1 min) to 
remove the excess fluorophore, 
anaesthetized in E2 media containing a 
few drops of Ethyl 3-aminobenzoate 
methanesulfonate (tricaine, Sigma 
Aldrich) solution for 30 seconds, and mounted in fresh E2 media on a glass slide.  Once on the 
slide, larvae were aligned using a hair loop so that they were lying on their side [Figure 12].  
Imaging consisted of counting the number of hair cells in each of the 3 most posterior tail 
neuromasts and acquiring representative images with one of two fluorescence microscope setups: 
Nikon Eclipse E600 microscope with a 100 W mercury lamp, a FITC filter, a ProgRes MF 
camera, and 4$, 10$, or 40$ air objectives; Olympus IX71 microscope with a 100 W mercury 
lamp, 525/30 nm emission filter and 460/40 excitation filter, and a 20$ air objective.  After 
imaging, larvae were returned to Petri dishes marked with their treatment group.   
Systemic Toxicity Assay 
 To assess the acute systemic toxicity of a single exposure to AuNP-cisplatin solutions, 5 
dpf zebrafish larvae were treated in AuNP-cisplatin samples containing between 6 and 8 #M 
cisplatin for varying lengths of time.  All AuNP-cisplatin solutions were suspended in 50 mM, 
pH = 8 tricine buffer.  There were 5 fish per treatment group, and the groups were: AuNP-
Figure 12. Example showing the orientation of 
larva on glass slides for fluorescence microscopy 
imaging of hair cells.  Image was taken through 
the lens of a Zeiss Stemi DV4 stereo microscope 
with an iPAD camera. 
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cisplatin for 24 hours, AuNP-cisplatin for 12 hours, AuNP cisplatin for 4 hours, MUA-capped 
AuNPs for 24 hours, and 50 mM, pH = 8 tricine buffer for 24 hours.  For each treatment group, 
all of the larvae were placed into a well in a 24-well plate containing 1 mL of the particular 
treatment solution.  After the treatment time was complete, the number of surviving fish in each 
group was counted.  The survival count was taken immediately after completion of the treatment, 
and did not take into account mortality occurring after this time that is still due to AuNPs 
exposure. 
Data Analysis 
 Statistical significance values were obtained by independent-means t-test or a one-way 
analysis of variance (ANOVA) with a 95% confidence level using SPSS statistics program.  
Tukey post-hoc comparisons were used to analyze the significance of differences found by the 
one-way ANOVA.  Statistical significance was set at p < 0.05.   
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Results and Discussion 
Gold Nanoparticle Synthesis  
 Gold nanoparticles of different sizes were synthesized using a seeded-growth strategy 
that was based on reversing the order of addition of reagents in the Turkevich method (Kimling, 
2006).  Gold seeds were made by adding an aqueous AuCl3 solution to a boiling solution of 
sodium citrate and allowing the reaction to run for ten minutes.  Then, the temperature of the 
solution was decreased to 90 °C for the purpose of inhibiting the nucleation of new AuNPs, and 
therefore narrowing the size distribution of NPs grown from the seeds (Bastus, 2011).  The 
seeded growth steps were carried out by sequentially adding more sodium citrate and AuCl3 and 
allowing the reaction to run for 30 minutes between steps.  The addition of Au3+ precursor with 
each growth step acidifies the solution, and the sodium citrate is added to act as a pH buffer in 
the reaction (Ji, 2007).  If the reaction solution becomes too acidic, then the carboxylic groups on 
the citrate molecules become protonated and can no longer provide electrostatic repulsion 
between NPs.  So, the citrate is really fulfilling three roles by additionally acting as a reducing 
agent and capping agent throughout the synthesis of AuNPs.  After synthesis, both Au seeds and 
AuNPs produced by subsequent growth tests were characterized. UV-vis spectroscopy was used 
to measure the optical properties of AuNPs solutions produced by the seeded growth synthesis 
[Figure 13].  For all solutions, the spectra show a symmetric SPR band that red shifts as a 
function of the number of growth steps.  It is well known as the diameter of particles in AuNPs 
solutions increases the SPR band of those solutions undergoes a red shift in correlation with size 
increase (Amendola, 2009).  The fact that the intensity of the SPR band increases with increasing 
number of growth steps also suggests that the seeded-growth strategy produces AuNPs of 
increasing size by performing additional growth steps on the seed solution.   
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Figure 13.  Spectral characterization of AuNPs produced by seeded-growth synthesis.   
(a) UV-vis absorption spectra of AuNPs obtained after different number of growth steps. The 
increased red shift of the surface plasmon resonance (SPR) band after additional growth steps is 
due to an increase in diameter of the AuNPs. All spectra are normalized at 400 nm to facilitate 
comparison. Zoom of peaks shown in the inset.  (b) Evolution of the SPR peak wavelength as a 
function of the growth step.  (c) A photograph of AuNPs solutions produced by different number 
of growth steps. 
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 Analysis of SEM images of Au seeds and AuNPs produced after two and six growth 
steps confirmed the growth of the nanoparticles [Figure 14].  The size of the AuNPs increased 
from 11.3 ± 1.2 nm as seeds to 14.9 ± 1.7 nm after 2 additions, and then to 22.1 ± 2.2 nm after 6 
additions.  In comparison, the group whose methods were being followed obtained AuNPs that 
increased from 13.5 ± 2.1 nm as seeds to 19.2 ± 2.6 nm after 2 additions, and then to 24.8.1 ± 3.4 
nm after 6 additions (Bastus, 2011).  While the standard deviations in diameter of the AuNPs 
produced in this experiment were lower than the standard deviations of the AuNPs produced by 
Bastus et al., the size distributions for the AuNPs in this experiment (Figure 14D-F) were not as 
narrow as the size distributions found by Bastus et al.  Another discrepancy between the studies 
is that Bastus et al. found that growth decreases as the particle size increases, but the AuNPs 
synthesized in this experiment showed a linear relationship between number of growth steps and 
particle size [Figure S1].  It is expected that AuNPs growth should significantly decrease as the 
particle size increases, because the rate of growth is determined by the ratio of gold atoms added 
and those present at the seed surface (Bastus, 2011).  Therefore, it is quite surprising that 
addition of a constant amount of gold to particles of increasing surface area led to linear AuNPs 
growth.  One possible explanation for the discrepancy between the growth-rate findings in this 
experiment and established knowledge about the rate of this reaction is that the SEM used in this 
experiment for imaging has far lower resolution than the TEM used by Bastus et al.  The 
relatively low resolution of the SEM could have resulted in imprecise measurements of AuNPs 
diameter.  Still, the data from SEM imaging was very valuable, as it allowed AuNPs grown from 
2 and 3 growth steps to be selected for further functionalization and use in the rest of the study.  
Also, attaining at least a rough measurement of AuNPs diameter was necessary for later 
calculations, such as the number of cisplatin molecules loaded per nanoparticle. 
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Figure 14.  Scanning Electron Microscope (SEM) images of AuNPs synthesized by different 
number of growths steps in the seeded-growth synthesis.  (a-c) SEM images of AuNPs              
obtained after 0 (Seeds), 2, and 6 growth steps, respectively. White scale bar in each image 
represents 200 nm.  (d-f) Size distribution histograms of AuNPs obtained after 0 (11.3±1.2 nm), 
2 (14.9±1.7 nm), and 6 (22.1±2.2 nm) growth steps, respectively. 100 NPs were measured for 
each group. The histogram insets show the appearance of AuNPs produced using that number of 
growth steps.  
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Gold Nanoparticle Functionalization 
 The process of attaching cisplatin to MUA-capped AuNPs to create an efficient antitumor 
drug was first proposed by Vazquez-Campos et al. (Vazquez-Campos, 2008) [Figure 15A].  The 
pH-sensitive bond between cisplatin and the linker molecule, MUA, promotes the release of 
cisplatin from AuNPs after endosomal uptake by tumor cells, which the conjugates preferentially 
accumulate near to due to the EPR effect.  After the seeded-growth synthesis, AuNPs were 
modified with a self-assembled monolayer (SAM) of MUA.  The gold-thiol linkages formed 
between MUA and the AuNPs displace the citrate molecules that had been capping the NPs.  The 
MUA SAM increases the electrostatic stability of the AuNPs relative to their citrate-capped 
form, as measured by %-Potential (Comenge, 2012), and also provides carboxylic groups for 
further functionalization.  UV-vis spectroscopy analysis showed that the SPR band of 2 growth 
step AuNPs shifted from 521 nm to 526 nm after MUA conjugation [Figure 15B].  Comenge et 
al. also reported a 5 nm red shift of the SPR band after conjugation of MUA to AuNPs 
(Comenge, 2012).   
 To enable increased cisplatin loading into AuNPs solution, the MUA-capped AuNPs 
were concentrated by a destabilization-resuspension process.  pH 2.6 glycine/HCl buffer was 
added to the AuNPs solution to destabilize the NPs by protonating the MUA carboxylic acids.  
The destabilized solution was centrifuged, the supernatant was removed, and the pellet of MUA-
capped AuNPs was resuspended in pH 8 tricine buffer.  Dialysis was then performed on the 
colloidal solution to remove the excess, unbound MUA.  UV-vis spectra of the MUA-capped 
AuNPs taken after concentration showed that the concentration process resulted in a 1 nm red 
shift of the solution’s SPR band [Figure 15B].  This finding suggests that slight aggregation 
could have occurred during the concentration process; although, the red shift could also just 
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reflect optical differences of the DI H2O and tricine buffer in which the preconcentration and 
concentrated MUA-capped AuNPs were diluted, respectively.  Comenge et al. reported 
concentrating the MUA-AuNPs by up to a factor of 50 (Comenge, 2012), but in this experiment 
the MUA-AuNPs could only be concentrated by a little more than a factor of 3, as measured by 
UV-vis absorbance [Figure 15B].  Noticeable concentration could only be achieved after 
increasing the centrifugation time from 2 minutes, as suggested by Comenge et al., to 30 
minutes, and even then the factor of concentration was far less than what was reported by 
Comenge et al.  To gain a better measure of the exact factor of concentration that was achieved, 
future studies should measure [Au] before and after concentration using ICP-OES, instead of 
UV-vis.  Ultimately, the concentration of cisplatin in the final drug-nanoparticle conjugate 
solution is limited by the concentration of NPs in the solution. 
 In the final synthetic step, MUA-capped AuNPs were functionalized with cisplatin 
through a coordinate covalent bond.  As mentioned earlier, it has been shown that AuNPs with 
covalently-bound cisplatin are far more stable in physiological media than those electrostatically 
bound with cisplatin.  Commercial cisplatin does not bind covalently with deprotonated MUA 
carboxylic groups on the NP, and instead forms an electrostatic attraction (Comenge, 2010).  To 
enable the formation of a covalent bond, aquated cisplatin, [Pt(H2O)2(NH3)](NO3)2, must be used 
in the conjugation reaction instead of commercial cisplatin.  H2O is a better leaving group than 
Cl-, which allows the aquated form of cisplatin to form covalent bonds with MUA carboxylic 
groups.  Excess aquated cisplatin is initially added so as to achieve homogenous surface 
coverage by the partial conjugation.  The conjugation reaction between aquated cisplatin and 
MUA-capped AuNPs must be carried out in solution with a pH between 8 (pKa value of MUA 
SAM) and 9 (pH at which aquated cisplatin is deprotonated to give less-reactive hydroxo   
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Figure 15.  AuNP Functionalization.  (a) Scheme showing the functionalization steps to produce 
the AuNPs-cisplatin conjugate drug delivery system, adapted from (Comenge, 2012). 
Photographs show the appearance of AuNPs at steps in functionalization process. (b) UV-vis 
spectra of AuNPs at the working conditions. Red-shift of the SPR peak occurs at the different 
stages of functionalization: the initial peak of 2 growth step, citrate-capped AuNPs shifted from 
521 nm to 526 nm after MUA conjugation, from 526 nm to 527 nm after concentration, and from 
527 nm to 529 nm after cisplatin conjugation. Zoom of peaks shown in inset.  
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complexes) to ensure formation of the conjugate (Comenge, 2012).  After attachment of aquated 
cisplatin, the SPR band of the MUA-capped AuNPs solution red shifts from 527 nm to 529 nm 
[Figure 15B].  In comparison, Comenge et al. observed a 1.5 nm red shift upon conjugation of 
aquated cisplatin to MUA-capped AuNPs (Comenge, 2012).  If too much aquated cisplatin is 
bound, then the negative charge of the MUA SAM is quenched and the AuNPs aggregate.  So, 
the aquated cisplatin conjugation reaction was stopped after 25 minutes by removing the excess, 
unbound aquated cisplatin by dialysis.  After completion of the synthesis of the AuNPs-cisplatin 
conjugates, the amount of drug loaded into the solutions was measured. 
 The concentration of both platinum and gold in the AuNPs-cisplatin conjugate solutions 
was measured using ICP-OES.  The goal of the project was to investigate whether conjugation to 
AuNPs reduces cisplatin’s ototoxicity, and to do so the same concentration of the free drug and 
the NP-drug conjugate had to be given to different treatment groups for comparison.  Therefore, 
it was essential to determine the concentration of cisplatin loaded onto the nanoparticles before 
the AuNPs-cisplatin conjugates were used in any in vivo assays.  The fact that cisplatin is a 
simple inorganic molecule with one platinum atom per molecule means that the molarity of 
cisplatin bound to AuNPs can be measured by the molarity of bound platinum.  To quantitatively 
determine the concentration of platinum and gold in the AuNPs-cisplatin solutions, the 
conjugates were first digested using 0.2 M nitric acid and then analyzed by ICP-OES.  ICP-OES 
Calibration curves are shown in Supplemental Information [Figure S2].  Ten AuNPs-cisplatin 
samples were analyzed, including five samples from 2 growth steps AuNPs (14.9 ± 1.7 nm) and 
five from 3 growth steps AuNPs (16.7 ± 1.9 nm).  One of the samples, Sample IX, was a AuNPs-
cisplatin solution that had not had the excess cisplatin removed by dialysis.  Sample IX was 
found to have vastly more platinum than any of the other dialyzed AuNPs-cisplatin solutions, 
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which revealed the effectiveness of the dialysis process.  For eight of the nine AuNP-cisplatin 
conjugate solutions (excluding Sample X) the drug loading was approximately the same as had 
previously been demonstrated Comenge et al., which was about 500 molecules of cisplatin per 
AuNP (Comenge, 2012) [Table 1].  This result was expected, because the AuNPs synthesis and 
functionalization process performed in this experiment was almost identical to the one employed 
by Comenge et al.  However, the total concentrations of platinum (up to 20.5 #M) and gold (up 
to 2680 #M) in all of the solutions were far lower than had been demonstrated by Comenge et al. 
(up to 380 #M Pt and 70 mM Au), because the AuNP concentration step was less successful. 
Table 1.  Analysis of AuNPs-cisplatin samples. NPs with a radius of 7.465 nm are from a two 
growth step synthesis, and NPs with a radius of 8.366 nm are from a three growth step synthesis. 
#Cisplatin/NP is given with calculated uncertainty (See Figure S4). See Table S1 also percent 
uncertainty values associated with these calculations. Even within the same synthetic 
methodology, samples differed greatly in both [Au] and [Pt] measurements. Samples I-VIII 
contained the expected number, based on past analysis of conjugates made using this synthetic 
scheme (Comenge, 2012) of cisplatin molecules loaded per AuNP. Sample IX contained 
drastically higher [Pt] because dialysis was not performed on this sample after addition of 
aquated cisplatin. Sample X contained higher [Pt] and a larger number of cisplatin/NP than all 
other dialyzed AuNPs-cisplatin samples.  * determined from SEM data; # determined from ICP-
OES data; $ calculated from SEM and ICP-OES data. 
 
 The greatly decreased gold molarity and number of NP/mL relative to the findings of 
Comenge et al. is likely a result of two factors.  First, the fact that the conjugates synthesized in 
this experiment had between 3.10$1012 and 1.11$1013 NP/mL after concentration while 
Solution Radius/NP (nm)* Au [uM]# Pt [uM]# #NP/mL$ x 1012 NP [nM]$ #Cisplatin/NP$
Sample I 7.465 1510 6.38 8.85 14.7 435 ± 210
Sample II 7.465 696 4.17 5.07 6.76 617 ± 200
Sample III 7.465 1550 6.07 9.07 15.1 403 ± 450
Sample IV 7.465 1310 6.36 7.67 12.7 500 ± 820
Sample V 8.366 2680 6.95 11.1 18.5 376 ± 3800
Sample VI 8.366 2480 7.14 10.3 17.1 418 ± 1100
Sample VII 8.366 1440 4.60 6.00 9.96 462 ± 130
Sample VIII 8.366 2070 7.25 8.60 14.3 507 ± 1900
Sample IX 8.366 745 195 3.10 5.14 38100 ± 8400
Sample X 7.465 745 20.5 4.36 7.24 2840 ± 580
 47 
Comenge’s conjugates reportedly had 5.5$1012 NP/mL before concentration suggests that 
AuNPs were synthesized in lower than expected initial concentrations.  Second, UV-vis spectral 
data showed that the concentration process performed in this experiment only increased the NP 
concentration by slightly more than a factor of three, which is a far lower factor of concentration 
than was achieved by Comenge et al (up to 50 times).  As expected there was more gold in the 
solutions of AuNPs from 3 growth steps than from 2 growth steps.  An independent-samples t-
test was conducted to compare the gold molarity of AuNPs-cisplatin solutions that had been 
made from AuNPs from 2 growth steps and 3 growth steps.  There was not a significant different 
in gold molarity for 2 growth step AuNPs-cisplatin solutions (1162 ± 414 #M) and 3 growth step 
AuNPs-cisplatin solutions (1883 ± 792 #M); t(8)=1.801, p=0.109; however, the difference was 
approaching significance.  However, none of the AuNPs-cisplatin solutions contained anywhere 
near the amount of AuNPs as the samples produced by Comenge et al.  Therefore, even though 
the conjugates synthesized in this experiment had the same per NP drug loading as the 
conjugates synthesized by Comenge et al., there was simply too low a concentration of AuNPs in 
the solutions to achieve the previously published cisplatin concentrations.   
 AuNPs-cisplatin Sample X stands out as appearing to have significantly more cisplatin 
(~20#M) bound to the NPs than any other the other solutions. Yet, the very high number of 
calculated cisplatin molecules per NP for Sample X (2840 ± 580 cisplatin/NP) indicates that 
something went wrong with this solution, because loading of more than about 500 cisplatin/ 15 
nm AuNP has never been achieved (Comenge, 2012).  It is possible that dialysis somehow failed 
for Sample X, which would explain the presence of excess platinum in the solution.  Or the 
AuNPs could have aggregated sometime before cisplatin conjugation, as it is known that as NPs 
grow the number of cisplatin that can be attached to their surface increases exponentially (Craig, 
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2012).  Either way, ICP-OES analysis revealed that AuNPs-cisplatin samples contained far less 
platinum than had been expected based on prior studies, and this finding meant that testing the 
ototoxicity of AuNPs-cisplatin conjugates at doses of cisplatin that cause hair cell lose was not 
feasible within the scope of this project.   
Zebrafish Toxicity Testing 
 The original goal of this study was to use larval zebrafish as an in vivo model to 
investigate whether conjugation to AuNPs reduces cisplatin’s ototoxicity.  Towards this end, it 
was first tested whether cisplatin kills larval zebrafish lateral line hair cells in a dose-dependent 
manner.  Small groups of zebrafish larvae were treated in 50 mM, pH = 8 tricine buffer 
containing different concentrations of cisplatin for 24 hours, according to an established 
procedure (Ton, 2005).  Many other groups performing cisplatin ototoxicity assays with 
zebrafish employ a 4 hour treatment period that requires up to 1 mM cisplatin to induce the same 
level of hair cell loss caused by treatment with 50 #M cisplatin for 24 hours (Ou, 2007; Uribe, 
2013).  The longer treatment time was employed in this study so that a lower concentration of 
cisplatin could be used to induce hair cell loss, and it is has been shown that the time of onset of 
hair cell death in the larval zebrafish lateral line is correlated with the dose of cisplatin delivered 
(Ou, 2007).  Ultimately, this meant that with a longer treatment time a lower concentration of the 
drug would need to be incorporated into the nanoparticle conjugates, because the purpose of the 
study was to test to the ototoxicity of AuNPs-cisplatin solutions in comparison with the 
ototoxicity of the same dose of free cisplatin. 
 Results of the 24 hour ototoxicity assay showed that cisplatin does induce the death of 
larval zebrafish lateral line hair cells in a dose dependent manner [Figure 16].  While treatment 
with 7 #M cisplatin solution did not cause noticeable hair cell death relative to the control tricine 
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buffer treatment, the two higher cisplatin concentration solutions (20 and 50 #M) both caused 
significant cell death [Figure 17A-C].  During the same assay, one group of 6 larvae was treated 
with AuNPs-cisplatin Sample X, and, although 2 of the larvae died during treatment, the 
survivors did not have significant hair cell loss [Figure 17E].  One-way ANOVA testing revealed 
a significant difference in number of hair cells between the treatment groups in the ototoxicity 
assay (F(4,61) = 146.47, p < 0.001).  A Tukey post-hoc test showed that there were no  
 
Figure 16.  Cisplatin-induced ototoxicity.  Dose response curve showing hair cell counts as a 
function of cisplatin concentration.  Zebrafish larvae (N=3-5 fish per group) were treated in 50 
mM, pH = 8 tricine buffer containing the indicated concentration of cisplatin for 24 hours. Then, 
larvae were stained with DiASP, a fluorophore that specifically labels hair cells, and imaged 
using fluorescence microscopy. Control larvae treated with 0 #M cisplatin were found to have 
10.7 ± 0.7 hair cells per neuromast, and hair cell counts for other groups is given as a percentage 
of the control. The blue circle indicates the concentration of Pt in the AuNPs-cisplatin sample 
used to treat larvae, which did not induce any hair cell loss (See Fig 17). 
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significant differences in hair cells counts for 
larvae in the control group, the 7 #M cisplatin 
group, and AuNPs-cisplatin Sample X group.  
However, larvae in the group treated with 50 
#M cisplatin had significantly fewer hair cells 
than all other groups (p < 0.001).  Larvae in 
the group treated with 20 #M cisplatin had 
significantly more hair cells than the 50 #M 
cisplatin group (p < 0.001), but significantly 
fewer hair cells than the other three groups (p 
< 0.001).     
 The ototoxicity assay provided 
important information, but was not able to 
produce definitive results about the ability of 
vehiculation to AuNPs to reduce cisplatin’s 
ototoxicity.  The finding that a 20 #M dose of 
cisplatin was able to cause a significant 
reduction in hair cell count relative to the 
control suggests that AuNPs-cisplatin samples 
containing as low as 20 #M can be used for in 
vivo zebrafish ototoxicity assays.  Initial analysis of ICP-OES data for elemental concentration 
showed that AuNPs-cisplatin Sample X contained 20.5 ±0.5 #M Pt [Table 1], and this sample 
was used for the ototoxicity assay on the assumption that it contained 20.5 #M cisplatin bound to 
Figure 17.  Cisplatin-induced ototoxicity hair 
cell images.  (a-e) DiASP-labelled bundles of 
hair cells of larvae treated in the 24 hour 
ototoxicity assay referenced in Figure 16. One 
representative image is shown per group.  For 
scale, average diameter of a hair cell is 5 #m. 
Images show increasing hair cell loss with 
increasing cisplatin dose, but no hair cell loss 
for control larvae or AuNP-cisplatin Sample X 
treated larvae. It was determined that this 
sample likely did not have as much as 20 #M 
cisplatin, as was calculated (Table 1), so it 
probably was not a positive result. All images 
taken at 20$ with an Olympus IX71 scope.  
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the AuNPs.  The very low uncertainty (2%) associated with the platinum concentration 
measurement shows the precision of this measurement [Table S1].  As mentioned previously, the 
high number of cisplatin molecules per NP in Sample X indicates it likely that either dialysis of 
excess cisplatin failed or aggregation of the AuNPs occurred prior to cisplatin conjugation.  If 
dialysis of excess cisplatin failed, then unbound cisplatin in the AuNPs-cisplatin solution would 
lose cytotoxicity within a few days, because cisplatin in solution isomerizes into its trans form 
transplatin, which has greatly reduced bioactivity (Wagstaff, 2012).  Therefore, failure of dialysis 
could explain why larvae treated with AuNPs-cisplatin Sample X showed no hair cell loss even 
though the solution had a concentration of platinum (20.5 #M) at which free cisplatin is known 
to cause hair cell death [Figure 17B,E].  If, instead of dialysis failure, aggregation of AuNPs 
before cisplatin addition explains the high drug loading per NP in Sample X, then the finding 
that treatment with this solution did not cause hair cell loss would support the hypothesis that 
conjugation to AuNPs can reduce cisplatin’s ototoxicity.  However, without SEM images from 
which to measure the exact diameter of AuNPs in Sample X, it is impossible to know whether 
aggregation of this sample did occur and allow the actual loading of over 2800 cisplatin 
molecules per NP.  Ultimately, results from the ototoxicity assay showed that cisplatin kills 
larval zebrafish hair cells at an over ten-fold lower concentration than achieved in AuNPs-
cisplatin conjugates by Comenge et al., which suggests that it should be possible to perform 
AuNPs-cisplatin ototoxicity testing in zebrafish.  Unfortunately, other than Sample X, none of 
the AuNPs-cisplatin samples produced in this experiment contained a high enough concentration 
of bound cisplatin that the same dose of the free drug is ototoxic. 
  The observation of 2 deaths out of the 6 larva treated for 24 hours with AuNPs-cisplatin 
Sample X prompted further testing of the systemic toxicity of the AuNPs-cisplatin conjugates to 
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zebrafish larvae.  ICP-OES analysis revealed that all of the AuNPs-cisplatin samples contained a 
greater concentration of gold than was used in any existing study of AuNPs with zebrafish 
[Table 1].  The AuNPs-cisplatin samples prepared in this experiment were all measured to 
contain greater than 5 nM NPs, while the AuNPs zebrafish toxicity studies referenced in this 
paper used no more than 2 nM NPs for treatment (Truong, 2012).  Seeing as how the toxicity of 
AuNPs has been shown to be dose dependent (Browning, 2012), the relatively high 
concentration of the AuNP-cisplatin conjugates suggested that they might cause greater toxicity 
than was observed in previous studies.  Smalls groups (n=4-6) of larvae were treated in the 
AuNPs-cisplatin solutions for either 4, 12, or 24 hours, and Table 2 gives the exact assignments 
of particular conjugate samples to the different treatment conditions, as well as the percent of 
larvae that survived in each sample [Table 2].  Larvae survival in the AuNPs-cisplatin 
solutions was found to generally decrease with time, but increasing the treatment time from 12 to 
24 hours did not appear to significantly effect the mortality rate [Figure 18].  Although the very  
Treatment Solution Treatment time (hr) N Fish Survival (%)
Sample I 4 4 75
Sample IV 4 5 80
Sample VI 12 4 25
Sample VIII 12 5 40
Sample II 24 4 50
Sample III 24 5 20
Sample V 24 6 17
Sample X 24 6 67
Table 2.  Systemic toxicity testing of different AuNPs-cisplatin samples. The sample names 
refer to data given in Table 1.  The average and standard deviation of percent survival were 78 
± 4% at 4 hours, 33 ± 11% at 12 hours, and 38 ± 24% at 24 hours.   
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Figure 18.  Larval zebrafish systemic toxicity caused by treatment with AuNPs-cisplatin 
conjugates. The percent of larvae surviving AuNPs-cisplatin treatment for varying lengths of 
time is shown. Percentage of fish surviving the treatment was counted immediately after 
completion of the treatment. The 4 hour data point comprises two separate experiments with a 
total of 9 larvae; the 12 hour data point comprises two separate experiments with a total of 9 
larvae; the 24 hour data point comprises four separate experiments with a total of 21 larvae. Only 
25% (two experiments, n=8) of larvae treated in concentrated solutions of AuNPs-MUA for 24 
hours survived (not shown), which indicates that it is likely that the systemic toxicity is due to 
the high concentration of AuNPs, instead of a specific trait of the AuNPs-cisplatin conjugates.   
 
small samples sizes weaken any conclusions that can be drawn, the finding that only ~35% of 
larvae treated for 12 or more hours survive indicates the AuNPs-cisplatin solutions used in this 
experiment were acutely toxic. While the large standard deviation for the 24 hour data points 
shows the need for more data collection with larger sample sizes, it appears as if the systemic 
toxicity is not significantly increased by increasing the treatment time past 12 hours.  To test 
whether the observed acute toxicity was due to the high concentrations of AuNPs themselves, 
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two groups with a total of eight larvae were treated in concentrated MUA-capped AuNPs 
solution for 24 hours.  While ICP-OES data was not available for the concentrated AuNPs-MUA 
solutions, UV-vis absorbance data suggests that these solutions contained very similar 
concentrations of NPs to the AuNPs-cisplatin solutions [Figure 15].  Only 25% of larvae 
survived the 24 hour treatment in AuNPs-MUA solution, which strongly suggests that the acute 
systemic toxicity observed in the larvae treated with the AuNPs-cisplatin solutions was an effect 
of the high concentrations of AuNPs.   
 The link between AuNPs solution concentration and zebrafish larvae toxicity was 
supported by the finding of a modest correlation between the concentration of gold in AuNPs-
cisplatin solutions and the acute systemic toxicity of those samples to zebrafish larvae [Figure 
19].  When the survival percentages of the four different groups treated with AuNPs-cisplatin 
solution for 24 hours were compared, it was found that concentration of gold in the solutions 
moderately predicted their acute toxicity to the larvae.  Given the prior similar finding of 
concentration-dependent AuNP toxicity in zebrafish, it is likely if this experiment had employed 
a greater number of groups in each treatment condition then the strength of the correlation 
between [Au] and acute zebrafish toxicity would have increased.  The systemic toxicity results 
suggest that AuNPs acute toxicity to zebrafish is dose dependent in the concentration range of 
approximately 5 to 20 nM AuNPs, which has been shown to be the case in the concentration 
range of 0.025 to 1.2 nM AuNPs (Browning, 2009).  The precision of the concentration data 
upon which this conclusion is based is demonstrated by the relatively low percent uncertainties 
associated with the ICP-OES gold concentration measurements [Table S1].  Considering the lack 
of published information available about the toxicity of 5 to 20 nM AuNPs to zebrafish and the  
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Figure 19.  Relationship between gold concentration and systemic toxicity of AuNPs. The four 
treatment groups whose data is shown here are the four groups that underwent 24 hour treatment 
with AuNPs-cisplatin conjugates referenced in Figure 18. Percentage of fish surviving the 
treatment was counted immediately after completion of the treatment. Although the sample size 
is small, it appears that there is at least a moderate correlation between the concentration of gold 
and the acute systemic toxicity of that sample to zebrafish larvae. A line of best fit is shown and 
its R2 valued is given.  
 
small sample sizes used in this experiment, data from additional experiments is necessary before 
firm conclusions can be made about the toxicity of AuNPs in this concentration range to 
zebrafish.  That being said, it appears as if concentrations of AuNPs above 5 nM are acutely 
toxic to zebrafish larvae, and the findings from this experiment provide evidence that this 
toxicity is concentration-dependent.   
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Conclusions 
 The intended goal of this project was to use larval zebrafish as an in vivo model to 
investigate whether conjugation to AuNPs reduces cisplatin’s ototoxicity.  AuNPs-cisplatin 
conjugates were prepared, but two factors prevented their use in larval zebrafish ototoxicity 
assays.  First, it was determined that the concentration of cisplatin bound to the conjugates was 
low enough that the same concentration of the free drug did not cause hair cell loss.  The low 
cisplatin concentration prevented ototoxicity testing because the assay required that the same 
dose of drug given in conjugate form causes hair cell loss in free form.  Second, it was found that 
the high concentration (>5 nM NPs) of AuNPs in the conjugate solutions was acutely toxic to 
zebrafish larvae over the 24 hour period required for ototoxicity testing.  The small samples sizes 
and high deviation of the results of the systemic toxicity testing means that more data needs to be 
gathered before conclusions can really be made about the toxicity of >5 nM AuNPs to zebrafish 
larvae.  Still, these initials results suggest that AuNPs at the concentrations used in this project 
are acutely toxic to zebrafish larvae.  The systemic toxicity of AuNPs-cisplatin conjugates found 
in this study is intriguing, because Comenge et al. found that conjugates synthesized using the 
same protocol caused no systemic toxicity or nephrotoxicity in an in vivo mouse experiment 
(Comenge, 2012).  The conjugates synthesized by Comenge et al. had up to 27 times higher 
AuNPs molarity than the conjugates prepared in this study, and yet they still did not induce 
systemic toxicity in mice upon i.p administration.   
 The different toxicities caused by AuNPs-cisplatin treatment in different model 
organisms both highlights the need for more studies to gather information about NP toxicity and 
also indicates that experiments using AuNPs at high concentrations should be performed using 
mice rather than zebrafish.  As was mentioned earlier, the inconclusive findings of existing 
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studies on the toxicity of AuNPs necessitates the execution of a greater quantity of more detailed 
toxicity studies in a wider range of model organisms (Khlebtsov, 2011).  Until more conclusive 
toxicity information is available, researchers will have to base experimental designs on the 
existing findings.  In this vein, a logical future project would utilize a mouse model to investigate 
whether conjugation to AuNPs reduces cisplatin’s ototoxicity, because mice appear to tolerate 
significantly higher concentrations of AuNPs treatments than do zebrafish.  It is possible that a 
contributing factor for why AuNPs-cisplatin solutions killed zebrafish larvae but tumor-bearing 
mice is that the biodistribution of the conjugates was altered by the EPR effect in the mice but 
not in the zebrafish.  The use of zebrafish as a model for malignant tumors is well established 
(Amatruda, 2002), and future studies testing the efficacy of AuNPs-drug conjugates in zebrafish 
should utilize tumor-bearing fish so that the EPR effect can occur.  However, before more 
AuNPs-drug conjugate testing is performed, thorough studies focusing on the acute systemic 
toxicity, and its concentration dependence, of AuNPs to zebrafish must be completed   
 Moving forward, the use of nanoparticles as delivery carriers to selectively target 
chemotherapeutic drugs to tumors is still very promising.  The EPR effect remains a well 
documented mechanism by which drugs can be targeted to tumors, and researchers have even 
found that this tumoritropism can be enhanced by pre-treatment with drugs such as 
vasoconstrictors (Iyer, 2006).  The passive targeting of NPs to tumors via the EPR effect has also 
been supplemented by the addition of tumor-targeting ligands, such as antibodies, to the NP 
surface that will also drive active targeting (Qian, 2008).  Some research groups have added an 
imaging component to the antibody-functionalized NPs that allows for tracking of cellular uptake 
of the nanoparticles, and these groups have found that the combination of both passive and active 
tumor targeting leads to increased tumor cell drug uptake when compared to passive targeting 
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alone (Yang, 2009).  The incredible precision of delivery achieved by the antibody-
functionalized NPs-drug conjugates indicates that these systems have great potential for reducing 
the toxicity of chemotherapeutic drugs.  Ultimately, the safety of these conjugates could be 
maximized by making the nanoparticle used for delivery out of a substance that is biodegradable 
with a lifespan that is limited to the therapeutic window of the drug being used (De Jong, 2008).  
Exciting work is being carried out to develop such biodegradable nanocarriers using genetically 
engineered drug material such as elastin-like polypeptides, silk-like polypeptides, and silk-
elastin-like protein polymers (Shi, 2014).  In the future, it is possible that biodegradable 
nanocarriers such as these will be used in the clinic to target the delivery of chemotherapeutic 
drugs like cisplatin to tumors, and therefore reduce chemotherapy’s toxic side effects. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
References 
Abu-Surrah A, Kettunen M (2006) Platinum group antitumor chemistry: design and development of new 
anticancer drugs complementary to cisplatin. Curr. Med. Chem. 13: 1337-57. 
Alderden R, Hall M, Hambley T (2006) The Discovery and Development of Cisplatin. J. Chem. Ed. 83: 
728-34. 
Amendola V, Meneghetti M (2009) Size Evaluation of Gold Nanoparticles by UV-vis Spectroscopy. J. 
Phys. Chem. C 113: 4277-85. 
Amutrada J, Shepard J, Stern H, Zon L (2002) Zebrafish as a cancer model system. Cancer Cell 1: 229-
31. 
Anderson C, Taylor I, Tibbetts M, Philpott J, Hu Y, Tanski J (2012) Hetero-multinuclear 
Ruthenium(III)/Platinum(II) Complexes That Potentially Exhibit Both Antimetastatic and Antineoplastic 
Properties. Inorganic Chemistry 51: 12917-24. 
Arany I, Safirstein R (2003) Cisplatin Nephrotoxicity. Seminars in Nephrology 23: 460-4. 
 
Bar-Ilan O, Albrecht R, Fako V, Furgeson D (2009) Toxicity Assessments of Multisized Gold and Silver 
Nanoparticles in Zebrafish Embryos. Small 5: 1897-910. 
 
Bastus N, Comenge J, Puntes V (2011) Kinetically Controlled Seeded Growth Synthesis of Citrate-
Stabilized Gold Nanoparticles of up to 200 nm: Size Focusing versus Ostwald Ripening. Langmuir 27: 
11098-105. 
 
Bates J, Mittge E, Kuhlman J, Baden K, Cheesman S, Guillemin K (2006) Distinct signals from the 
microbiota promote different aspects of zebrafish gut differentiation. Developmental Biology 297: 374-86. 
Borch R, Markman M (1989) Biochemical modulation of cisplatin toxicity. Pharmacology & 
Therapeutics 41: 371-380. 
 
Bozich J, Lohse S, Torelli M, Murphy C, Hamers R, Klaper R (2014) Surface chemistry, charge and 
ligand type impact the toxicity of gold nanoparticles to Daphnia magna. Env. Sci. Nano DOI: 
10.1039/c4en00006d. 
 
Braydich-Stolle L, Hussain S, Schlager J, Hofmann M (2005) In Vitro Cytotoxicity of Nanoparticles in 
Mammalian Germline Stem Cells. Toxicological Sciences 88: 412-9. 
 
Browning L, Lee K, Huang T, Nallathamby P, Lowman J, Xu N (2009) Random Walk of Single Gold 
Nanoparticles in Zebrafish Embryos Leading to Stochastic Toxic Effects on Embryonic Developments. 
Nanoscale 1: 138-52. 
 
Cardinaal R, de Groot J, Huizing E, Veldman J, Smoorenburg G (2000) Cisplatin-induced ototoxicity: 
morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? Hearing Research 
144: 147-56. 
 
Chaney S, Campbell S, Temple B, Bassett E, Wu Y, Faldu M (2004) Protein interactions with platinum-
DNA adducts: from structure to function. J. Inorg. Biochem. 98: 1551-9. 
 
 60 
Chen Y, Hung Y, Liau I, Huang S (2009) Assessment of the In Vivo Toxicity of Gold Nanoparticles. 
Nanoscale Res. Lett. 4: 858-64.  
 
Chithrani B, Ghazani A, Chan W (2006) Determining the Size and Shape Dependance of Gold 
Nanoparticle Uptake into Mammalian Cells. Nano Letters 6: 662-8. 
 
Cleeland C, Allen J, Roberts S, Brell J, Giralt S, Khakoo A, Kirch R, Kwitkowski V, Liao Z, Skillings J 
(2012) Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nature Reviews Clinical 
Oncology 9: 471-8. 
 
Comenge J, Romera F, Sotelo C, Dominguez F, Puntes V (2010) Exploring the binding of Pt drugs to 
gold nanoparticles for controlled passive release of cisplatin. Journal of Controlled Release 148: e31-e32. 
 
Comenge J, Sotelo C, Romero F, Gallengo O, Barnadas A, Parada T, Dominguez F, Puntes V (2012) 
Detoxifying Antitumoral Drugs via Nanoconjugation: The Case of Gold Nanoparticles and Cisplatin. 
PLoS ONE 7: 1-15. 
 
Connor E, Mwamuka J, Gole A, Murphy C, Wyatt M (2005) Gold Nanoparticles Are Taken Up by 
Human Cells but Do Not Cause Acute Toxicity. Small 1: 325-7.   
 
Craig G, Brown S, Lamprou D, Graham D, Wheate N (2012) Cisplatin-Tethered Gold Nanoparticles That 
Exhibit Enhanced Reproducibility, Drug Loading, and Stability: a Step Closer to Pharmaceutical 
Approval? Inorganic Chemistry 51: 3490-7. 
 
Dabholkar M, Bostick-Bruton F, Weber C, Bohr V, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 
expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst. 84: 1512-7. 
 
Dambly-Chaudiere C, Sapede D, Soubiran F, Decorde K, Gompel N, Ghysen A (2003) The lateral line of 
zebrafish: a model system for the analysis of morphogenesis and neural development in vertebrates. 
Biology of the Cell 95: 579-87. 
 
Dand N, Patel P, Ayre A, Kadam V (2013) Polymeric micelles as a drug carrier for tumor targeting. 
Chronicles of Young Scientists 4: 94-101. 
 
Davies M, Berners-Price S, Hambley T (2000) Rates of platination of –AG- and –GA- containing double-
stranded oligonucleotides: effect of chloride concentration. J. Inorg. Biochem. 79: 167-72. 
 
De Jong W, Borm P (2008) Drug delivery and nanoparticles: Applications and hazards. International 
Journal of Nanomedicine 3: 133-49. 
 
Dreher M, Liu W, Michelich C, Dewhirst M, Yuan F, Chilkoti A (2006) Tumor Vascular Permeability, 
Accumulation, and Penetration of Macromolecular Drug Carriers. J. Nat. Can. Inst. 98: 335-44. 
 
Eastman A (1987) The formation, isolation, and characterization of DNA adducts produced by anticancer 
platinum complexes. Pharmacology & Therapeutics 34: 155-66. 
 
Eckardt J, Bentsion D, Lipatov O, Polyakov I, Mackintosh F, Karlin D, Baker G, Breitz H (2009) Phase II 
study of picoplatin as second-line therapy for patients with small-cell lung cancer. J. Clin. Oncol. 27: 
2046-51. 
 
 61 
Fang J, Sawa T, Maeda H (2003) Factors and mechanism of "EPR" effect and the enhanced antitumor 
effects of macromolecular drugs including SMANCS. Adv. Exp. Med. Biol. 519: 29-49. 
 
Farnsworth R, Lackmann M, Achen M, Stacker S (2013) Vascular remodeling in cancer. Oncogene,  adv. 
epub doi:10.1038. 
 
Faucherre A, Pujol-Marti J, Kawakami K, Lopez-Schier H (2009) Afferent Neurons of the Zebrafish 
Lateral Line Are Strict Selectors of Hair-Cell Orientation. PLoS ONE 4: e4477. 
Ferry K, Hamilton T, Johnson S (2000) Increased nucleotide excision repair in cisplatin-resistant ovarian 
cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 60: 1305-13. 
 
Fettiplace R (2009) Defining features of the hair cell mechanoelectrical transducer channel. Journal of 
European Physiology 458: 1115-1123. 
 
Filipski K, Loos W, Verweij J, Sparreboom A (2008) Interaction of Cisplatin with the human organic 
cation transporter 2. Clin. Cancer Res. 14: 3875-80. 
 
Fleming A, Alderton W (2013) Zebrafish in pharmaceutical industry research: finding the best fit. Drug 
Discovery Today: Disease Models 10: e43-50. 
 
Fraval H, Roberts J (1979) Excision Repair of cis-Diamminedichloroplatinum(II)-induced damage to 
DNA of Chinese Hamster Cells. Cancer Res. 39: 1793-7. 
 
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular 
Mechanisms of cisplatin resistance. Oncogene 31: 1869-83. 
 
Gasser G, Ott I, Metzler-Nolte N (2011) Organometallic Anticancer Compouds. J. Med Chem. 54: 3-25. 
 
Gately D, Howell S (1993) Cellular accumulation of the anticancer agent cisplatin: A review. Br. J. 
Cancer 67: 1171-6. 
 
Gerber D (2008) Targeted Therapies: A New Generation of Cancer Treatments. American Family 
Physician 77: 311-319. 
 
Ghosh P, Han G, De M, Kim C, Rotello V (2008) Gold Nanoparticles in delivery applications. Advanced 
Drug Delivery Reviews 60: 1307-15. 
 
Greish K "Chapter 3: Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine 
Drug Targeting." Cancer Nanotechnology: Methods and Protocols. By Stephen R. Grobmyer and Brij M. 
Moudgil. New York: Humana, 2010. 25-37.  
 
Haiss W, Thanh N, Aveyard J, Fernig D (2007) Determination of Size and Concentration of Gold 
Nanoparticles from UV-Vis Spectra. Analytical Chemistry 79: 4215-21. 
 
Hakkinen H (2012) The gold-sulfur interface at the nanoscale. Nature Chemistry 4: 443-55. 
 
Hambley T (2007) Metal-Based Therapeutics. Science 318: 1392-3. 
 
Hawkins R, Lovett M (2004) The developmental genetics of auditory hair cells. Hum. Mol. Genet. 13: 
289-96. 
 62 
 
Hincal A, Long D, Repta A (1979) Cisplatin stability in aqueous parenteral vehicles. J. Parenter. Drug 
Assoc. 33: 107-16. 
 
Holzer A, Manorek G, Howell S (2006) Contribution of the major copper influx transporter CTR1 to the 
cellular accumulation of cisplatin, carboplatin and oxaliplatin. Molec. Pharmacol. 70: 1390-4. 
 
Ishida S, Lee J, Thiele D, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the 
copper transporter Ctr1 in yeast and mammals. PNAS 99: 14298-302. 
 
Iyer A, Khaled G, Fang J, Maeda H (2006) Exploiting the enhanced permeability and retention effect for 
tumor targeting. Drug Discovery Today 11: 812-8. 
 
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D (2011) Global Cancer Statistics. CA: A Cancer 
Journal for Clinicians 61: 69-90. 
 
Ji X, Song X, Li J, Bai Y, Yang W, Peng X (2007) Size control of gold nanocrystals in citrate reduction: 
the third role of citrate. J. Am. Chem. Soc. 14: 13939-48. 
 
June C, Rosenberg S, Sadelain M, Weber J (2012) T-cell therapy at the threshold. Nature Biotechnology 
30: 611-14.   
 
Jung Y, Lippard S (2007) Direct Cellular Responses to Platinum-Induced DNA Damage. Chemical 
Reviews 107: 1387-407. 
 
Kelland L (1993) New platinum antitumor complexes. Crit. Rev. Oncol. Hematol. 15: 191-219. 
 
Kelland L (2002) Overcoming resistance to platinum therapy in patients with advanced cancer. Am. J. 
Cancer 1: 247-55. 
 
Kelland L (2007) The Resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer 7: 
573-84. 
 
Khlebtsov N, Dykman L (2011) Biodistribution and toxicity of engineered gold nanoparticles: a review of 
in vitro and in vivo studies. Chemical Society Reviews 40: 1647-71. 
 
Kimling J, Maier M, Okenve B, Kotaidis V, Ballot H, Plech A (2006) Turkevich Method for Gold 
Nanoparticle Synthesis Revisited. J. Phys. Chem. B 110: 15700-07. 
Knight K, Kraemer D, Winter C, Neuwelt E (2007) Early Changes in Auditory Function As a Result of 
Platinum Chemotherapy: Use of Extended High-Frequency Audiometry and Evoked Distortion Product 
Otoacoustic Emissions. J. Clin. Oncol. 26: 1190-5. 
 
Ko A, Dito E, Schillinger B, Venook A, Xu Z, Bergsland E, Wong D, Scott J, Hwang J, Tembero M 
(2008) A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and 
low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? 
Investigational New Drugs 26: 463-71. 
 
Lasagna-Reeves C, Gonzalez-Romero D, Barria M, Olmedo I, Clos A, Sadagopa Ramanujam V, 
Urayama A, Vergara L, Kogan M, Soto C (2010) Bioaccumulation and toxicity of gold nanoparticles after 
administration in mice. Biochemical and Biophysical Research Communications 393: 649-55. 
 63 
 
Lawrence C (2007) The husbandry of zebrafish (Danio rerio): A review. Aquaculture 269:1-20. 
Li Y, Womer R, Silber J (2004) Predicting cisplatin ototoxicity in children: influence of age and the 
cumulative dose. Eur. J. Cancer 40: 2445-51. 
 
Lim Z, Li J, Ng C, Yung L, Bay B (2011) Gold nanoparticles in cancer therapy. Acta Pharmacologica 
Sinica 32: 983-90. 
 
Litterst C, Torres I, Guarino A (1977) Plasma levels and organ distribution of platinum in the rat, dog, 
and dog fish following intravenous administration of cis-DDP(II). J. Clin. Hemat. Oncol. 7: 169-79. 
 
Loehrer P, Einhorn L (1984) Drugs five years later. Cisplatin. Ann. Intern. Med. 100: 704-13. 
 
Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: an anlysis of the literature. 
Ann. Oncol. 9: 13-21. 
 
Lopez-Schier H, Hudspeth A (2006) A two-step mechanism underlies the planer polarization of 
regenerating sensory hair cells. PNAS. 103: 18615-20. 
Love C, Estroff L, Kriebel J, Nuzzo R, Whitesides G (2005) Self-Assembled Monolayers of Thiolates on 
Metals as a Form of Nanotechnology. Chem. Rev. 105: 1103-69. 
 
Love R, Leventhal H, Easerling M, Nerenz D (1989) Side effects and emotional distress during cancer 
chemotherapy. Cancer 63: 604-12. 
 
Luqmani Y (2005) Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 14 Suppl. 
1: 35-48. 
 
Maeda H, Matsumura T, Konnno T, Iwai K, Ueda M (1984) Tailor-making of protein drugs by polymer 
conjugation for tumor targeting: a brief review on smancs. J. Protein Chem. 3: 181-93. 
 
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect 
in macromolecular therapeutics: a review. Journal of Controlled Release 65: 271-84. 
 
Maeda H (2012) Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. Journal 
of Controlled Release 164: 138-144. 
 
Maruyama K (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR 
effects. Advanced Drug Delivery Reviews 63: 161-9. 
 
Matsumura Y, Maeda H (1986) A New Concept for Marcomolecular Therapeutics in Cancer 
Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. 
Cancer Research 46: 6387-92. 
 
Miller R, Tadagavadi R, Ramesh G, Reeves W (2010) Mechanisms of Cisplatin Nephrotoxicity. Toxins 2: 
2490-2518. 
 
Mistry P, Kelland L, Abel G, Sidhar S, Harrap K (1991) The relationships between glutathione, 
glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian 
carcinoma cell lines. Br. J. Cancer 64: 215-20. 
 64 
 
Mironava T, Hadjiargyrou M, Simon M, Jurukovski V, Rafailovich M (2010) Gold nanoparticles cellular 
toxicity and recovery: Effect of size, concentration and exposure time. Nanotoxicology 4: 120-37. 
 
Moon I, So J, Jung Y, Lee W, Kim E, Choi J, Kim C, Choi J (2011) Fucoidan promotes mechanosensory 
hair cell regeneration following amino glycoside-induced cell death. Hearing Research 282: 236-42. 
Narayanan K, Sakthivel N (2008) Coriander leaf mediated biosynthesis of gold nanoparticles. Materials 
Letters 62: 4588-90. 
Nel A, Madler L, Velegol D, Xia T, Hoek E, Somasundaran P, Klaessig F, Castranova V, Thompson M 
(2009) Understanding biophysicochemical interactions at the nano–bio interface Nature Materials 8: 543-
557. 
 
Ou H, Raible D, Rubel E (2007) Cisplatin induced hair cell loss in zebrafish (Danio rerio) lateral line. 
Hearing Research 233: 46-53. 
 
Paciotti G, Myer L, Weinrich D, Goia D, Pavel N, McLaughlin R, Tamarkin L (2004) Colloidal gold: a 
novel nanoparticle vector for tumor directed drug delivery. Drug Delv. 11: 169-183.   
 
Pegram M, Lipton A, Hayes D, Weber B, Baselga J, Tripathy D, Baly D, Baughman S, Twaddell, Glaspy 
J, Slamon D (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized 
anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing 
metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16: 2659-71.  
 
Peyrone M (1844) Ueber die Einwirkung des Ammoniaks auf Platinchlorür. Justus Liebigs Annalen der 
Chemie 51: 1-29. 
 
Pinto A, Lippard S (1985) Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to 
DNA. Biochim. Biophys. Acta. 780: 167-80. 
 
Qian X, Peng X, Ansari D, Yin-Goen Q, Chen G, Shin D, Yang L, Young A, Wang M, Nie S (2008) In 
vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature 
Biotechnology 26: 83-90. 
 
Rabik C, Dolan E (2007) Molecular mechanisms of resistance and toxicity associated with platinating 
agents. Caner Treatment Reviews 33: 9-23. 
 
Ravi L, Somani S, Rybak L (1995) Mechanism of Cisplatin Ototoxicity: Antioxidant System. 
Pharmacology & Toxicology 76: 386-94. 
 
"Research at Dordick J. S. Group." Research at Dordick J. S. Group. RPI Chemical Engineering 
Department, n.d. Web. 26 Apr. 2014. 
 
Rodriguz-Fernandez J, Perez-Juste J, de Abajo J, Liz-Marzan L (2006) Seeded Growth of Submicron Au 
Colloids with Quadrupole Plasmon Resonance Modes. Langmuir 22: 7007-10. 
 
Rosenberg B, VanCamp L, Krigas T (1965) Inhibition of Cell Division in Escherichia Coli by 
Electrolysis Products from a Platinum Electrode. Nature 205: 698-9. 
 
 65 
Rosenberg B, Renshaw E, VanCamp L, Hartwick J, Drobnik J (1967) Platinum-induced filamentous 
growth in Escherichia coli. Journal of Bacteriology 93: 716-21. 
 
Rosenberg B, VanCamp L, Trosko J, Mansour V (1969) Platinum compounds: a new class of potent 
antitumor agents. Nature 222: 385-6. 
 
Ruoslahti E, Bhatia S, Sailor M (2010) Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188: 
759-68. 
 
Rybak L, Whitworth C, Mukherjea D, Ramkumar V (2007) Mechanisms of cisplatin-induced ototoxicity 
and prevention. Hearing Research 226: 157-67. 
 
Rybak L, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin Ototoxicity and Protection: Clinical and 
Experimental Studies. Tohoku J. Exp. Med. 219: 177-86.   
 
Samimi G, Safaei R, Katano K, Holzer A, Rochdi M, Tomioka M, Goodman M, Howell S (2004) 
Increased Expression of the Copper Efflux Transpoter ATP7A Mediates Resistance to Cisplatin, 
Carboplatin, and Oxaliplatin in Ovarian Cancer Cells. Clin. Can. Res. 10: 4661-9.  
 
Scott A, Wolchock J, Old L (2012) Antibody therapy of cancer. Nature Reviews Cancer 12: 278-87. 
 
Siddik Z (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 
7265-79.  
 
Shi P, Gustafson J, MacKay J (2014) Genetically engineered nanocarriers for drug delivery. Int. J. 
Nanomedicine 9: 1617-26. 
 
Sorenson C, Eastman A (1988) Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: 
role of G2 arrest and DNA double-strand breaks. Cancer Res. 48: 4484-8. 
 
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. 
Cancer 8: 473-80. 
 
Svenson S (2009) Dendrimers as a versatile platform in drug delivery applications. Euro. J. of 
Pharmaceutics and Biopharmaceutics 71: 445-462. 
 
Takakura Y, Hashida M (1996) Macromolecular Carrier Systems for Targeted Drug Delivery: 
Pharmacokinetic Considerations on Biodistribution. Pharmaceutical Research 13: 820-31.   
 
Thomas A, Hailey D, Stawicki T, Wu P, Coffin A, Rubel E, Raible D, Simon J, Ou H (2013) Functional 
Mechanotransduction Is Required for Cisplatin-Induced Hair Cell Death in the Zebrafish Lateral Line. J. 
Neurosci. 33: 4405-4414. 
 
Tomuleasa C, Soritau O, Orza A, Dudea M, Petrushev B, Mosteanu O, Susman S, Florea A, Pall E, Aldea 
M, Kacao G, Cristea V, Breidan-Neagoe I, Irimie A (2012) Gold Nanoparticles Conjugated with 
Cisplatin/Doxorubicin/Capecitabine Lower the Chemoresistance of Hepatocellular Carcinoma-Derived 
Cancer Cells. Journal of Gastrointestinal and Liver Disease 21: 187-96. 
 
Ton C, Parng C (2005) The use of zebrafish for assessing ototoxic and otoprotective agents. Hearing 
Research 2008: 79-88. 
 
 66 
Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Advanced Drug 
Delivery 63: 131-5. 
 
Truong L, Saili K, Miller J, Hutchinson J, Tanguay R (2012) Persistent adult zebrfish behavioral deficits 
results from acute embryonic exposure to gold nanoparticles. Comparitive Biochemistry and Physiology, 
Part C 155: 269-74. 
 
Truong L, Tilton S, Zaikova T, Richman E, Waters K, Hutchison J, Tanguay R (2013) Surface 
functionalities of gold nanoparticles impact embryonic gene expression responses. Nanotoxicology 7: 
192-201. 
 
Trzaska S (2005) Cisplatin. C&EN News 83(25). 
 
Uribe P, Mueller M, Gleichman J, Kramer M, Wang Q, Sibrian-Vazquez, Strongin R, Steyger P, 
Cotanche D, Matsui J (2013) Dimethyl Sulfoxide (DMSO) Exacerbates Cisplatin-induced Sensory Hair 
Cell Death in Zebrafish (Danio rerio). PLoS ONE 8: e55359 1-11. 
 
Varmus H (2006) The new era in cancer research. Science 312: 1162-1165.  
 
Vazquez-Campos S, Bastus N, Comenge J, Romero F, Sotelo C, Garcia F, Gallego O, Garcia A, 
Dominguez F, Puntes V (2008) Gold Nanoparticles as carriers of cisplatin: A new approach for cancer 
treatment. Trends in Nanotechnology Conference, abstrasct. 
Vlastis A, Simon J, Raible D, Rubel E, Owens K (2012) Screen of FDA-approved drug library reveals 
compounds that protect hair cells from aminoglycosides and cisplatin. Hearing Research 294: 153-65. 
Wagstaff A, Brown S, Holden M, Craig G, Plumb J, Brown R, Schreiter N, Chrzanowski W, Wheate W 
(2012) Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting 
with external magnetic fields. Inorganica Chimica Acta, 393, 328-33. 
Wang D, Lippard S (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 
4:307-20. 
 
Werner A (1893) Beitrag zur Konstitution anorganischer Verbindungen. Z. Anorg. Chem. 3: 267-330. 
 
Woehrle G, Brown L, Hutchison J (2005) Thiol-Functionalized, 1.5-nm Gold Nanoparticles through 
Ligand Exchange Reactions: Scope and Mechanism of Ligand Exchange. J. Am. Chemical Society 127: 
2172-83. 
 
Xue X, Hall M, Zhang Q, Wang P, Gottesman M, Liang X (2013) Nanoscale Drug Delivery Platforms 
Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking. 
ACS NANO 7: 10452-64. 
 
Yang L, Mao H, Wang A, Cao Z, Peng X, Wang X, Duan H, Ni C, Yuan Q, Adams G, Smith M, Wood 
W, Gao X, Nie S (2009) Single Chain Epidermal Growth Factor Receptor Antibody Conjugated 
Nanoparticles for in vivo Tumor Targeting and Imaging. Small. 5: 235-43. 
 
Zon L, Peterson R (2005) In Vivo Drug Discovery in the Zebrafish. Nature Reviews Drug Discovery 4: 
35-44. 
 
 67 
Supplementary Information  
 
Supplementary Figure 1. Linear relationship between number of growth steps in seeded-growth 
synthesis and diameter of AuNPs produced. Diameter measurements made from SEM images 
(Figure 14) using image analysis software ImageJ. It was expected that growth in diameter per 
growth step would decrease with increased number of growth steps, but this was not observed.   
 
Supplementary Table 1.  Percent uncertainties associated with the calculations given in Table 1 
of the text.   
Solution Radius/NP (nm) Au [uM] Pt [uM] #NP/mL x 1012 NP [nM] #Cisplatin/NP
Sample I 11 5 45 20 20 49
Sample II 11 14 22 24 24 33
Sample III 11 6 110 21 21 112
Sample IV 11 9 163 22 22 164
Sample V 11 5 1018 20 20 1018
Sample VI 11 1 274 20 20 275
Sample VII 11 17 11 26 26 28
Sample VIII 11 3 381 20 20 382
Sample IX 11 10 2 22 22 22
Sample X 11 5 2 20 20 20
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Supplementary Figure 2. Calibration curves for ICP-OES analysis of [Au] and [Pt]. Standard 
solutions made by serial dilutions of 1000 ppm stocks in 0.2 M HNO3. 
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Supplementary Figure 3.  Comparison between IR spectra of aquated cisplatin (top) and 
commercial cisplatin (bottom).  Differences between the two spectra help to confirm the 
synthesis of aquated cisplatin. 
 
 
 
 
 
 
 
 
